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“Every great scientific truth goes through three stages.  
First, people say it conflicts with the Bible.  
Next they say it has been discovered before.  
Lastly they say they always believed it.” 
 
Louis Agassiz (1807-1873) 
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1. Summary 
Transplanted mesenchymal stromal cells (MSC) have been reported to improve functional 
recovery after spinal cord injury (SCI). The mechanism(s) responsible for this effect are, 
however, largely unknown. The first studies about MSC transplantation into spinal cord 
lesions reported differentiation of the donor cells to a neural lineage. This so-called 
transdifferentiation capacity has aroused great excitement as well as great scepticism. Other 
studies suggested that the beneficial effects were due to a paracrine mechanism. This thesis 
was designed to provide insights into the properties of MSC as well as into their fate and 
function after transplantation into spinal cord lesions. 
Human MSC (hMSC) were found to constitutively express several neural-related markers, a 
property which may have led other groups to conclude that they were capable of 
transdifferentitation to a neural lineage. Interestingly, these markers demonstrated a donor-
dependent variability which may have influenced the widely differing opinions about hMSC 
transdifferentiation. 
Clinical application of hMSC requires the expansion of isolated cells to relevant numbers 
without supplementation of animal- or donor-derived serum. Conventional expansion, 
however, includes the employment of 10% fetal bovine serum (FBS) which might transfer 
infectous agents or might lead to the immune rejection of transplanted cells. The isolation 
and expansion of hMSC in the absence of serum supplementation was attempted in the 
present thesis but could not be accomplished. However, significantly better proliferation 
could be achieved with supplementation of only 2% FBS and certain growth factors 
compared to the conventional medium. The multipotent capacity of hMSC was found to be 
unaffected by the employment of this serum-reduced medium. 
Since the beneficial effects of hMSC transplantation into SCI were thought to be due to 
paracrine mechanisms, the expression patterns for several growth factors and cytokines 
were investigated. A donor-dependent variability of expression could be demonstrated in 
untreated hMSC as well as in hMSC that had been exposed to lipopolysaccharide (LPS). To 
investigate the possibility that hMSC could change their specific expression pattern when 
implanted into debris-laden spinal cord lesions, hMSC were co-cultivated with tissue 
homogenates from normal and injured rat spinal cords. To determine if this possibility might 
be tissue specific, homogenates from normal and infarcted rat heart were also applied. None 
of the above homogenates were found to change the individual donor-dependent patterns of 
growth factor- or cytokine expression suggesting that indivual hMSC expression patterns 
remained unaltered following implantation into the lesioned spinal cord. However, such 
donor-dependent variability might have a profound influence on the degree of subsequent 
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functional recovery and it has to be considered that some donor samples might not have the 
appropriate growth factor and cytokine expression profiles for optimal tissue repair. 
A major aspect of the present thesis was the evaluation of an hMSC-based tissue 
engineering strategy to promote orientated axonal re-growth and functional tissue repair in 
an experimental animal model of acute SCI. Therefore, cooperation partners transduced 
hMSC to express green fluorescent protein (GFP) to enable identification of transplanted 
cells. These cells were seeded into oriented 3D collagen scaffolds and implanted into 
thoracic spinal cord hemisections. Already 1 week after implantation, animals which received 
hMSC-seeded scaffolds demonstrated better functional improvement than the control 
animals, which was even significant after four weeks. This difference, however, was no 
longer significant at 8 weeks. Immunohistochemistry revealed that only small numbers of 
transplanted hMSC had survived up to the termination date of 8 weeks after implantation. 
Nonetheless, animals receiving hMSC-seeded scaffolds demonstrated increased numbers 
of regenerating axons as well as reduced astrocytic and inflammatory responses. 
Interestingly, donor hMSC were found to express chondroitin sulphate proteoglycans 
(CSPG) and although few viable cells could be detected, CSPG deposits could be observed 
throughout the scaffold. 
In conclusion, it is likely that hMSC exert their regenerative properties by the expression of 
growth factors, cytokines and extracellular matrix molecules which are capable of influencing 
resident and invading cells.  
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2. Zusammenfassung 
Transplantierte mesenchymale Stromazellen (MSZ) sind in der Lage die funktionelle 
Regeneration nach Rückenmarksverletzungen zu verbessern. Die verantwortlichen 
Mechanismen für diesen Effekt sind jedoch weitgehend unbekannt. Die ersten Studien über 
die Transplantation von MSZ in Läsionen des Rückenmarks zeigten eine Differenzierung der 
Spenderzellen in eine neurale Linie. Dieses so genannte Transdifferenzierungsvermögen 
rief enorme Aufregung aber auch große Skepsis hervor. Andere Studien kamen zu dem 
Schluss, dass der postive Effekt durch einen parakrinen Mechanismus hervorgerufen wird. 
Diese Dissertation wurde erstellt, um Einblicke in die Eigenschaften von MSZ sowie deren 
Schicksal und Funktion nach der Transplantation in Rückenmarksverletzungen zu erhalten.  
Es konnte festgestellt werden, dass humane MSZ (hMSZ) grundsätzlich einige neurale 
Marker exprimieren, eine Eigenschaft die andere Gruppen dazu verleitet haben mag zu 
folgern, dass hMSZ in eine neurale Linie transdifferenzieren können. Interessanterweise 
konnte nachgewiesen werden, dass diese Marker eine Spender-abhängige Variabilität 
aufweisen, die die weitgehend unterschiedlichen Meinungen über die Transdifferenzierung 
von hMSZ beeinflusst haben könnte.  
Die klinische Anwendung von hMSZ erfordert die Expansion der isolierten Zellen in 
entsprechender Anzahl ohne die Ergänzung von tierischem oder humanem Serum. Die 
konventionelle Expansion beinhaltet jedoch die Verwendung von 10% fötalem Kälberserum 
(FKS), welches infektiöse Erreger übertragen oder zu einer immunologischen 
Abstoßungsreaktion der transplantierten Zellen führen könnte. In der vorliegenden 
Dissertation wurde die Isolation und Expansion von hMSZ ohne Ergänzung von Serum 
angestrebt, konnte jedoch nicht erzielt werden. Allerdings konnte im Vergleich zum 
konventionellen Medium eine signifikant bessere Proliferation mit der Ergänzung von nur 2% 
FKS und bestimmten Wachstumsfaktoren erreicht werden. Die Multipotenz der hMSZ wurde 
durch die Verwendung dieses Serum-reduzierten Mediums nicht beeinflusst.   
Da die förderlichen Eigenschaften der hMSZ Transplantation in Rückenmarksverletzungen 
die Folge von parakrinen Mechanismen zu sein scheinen, wurde das Expressionsmuster 
verschiedener Wachstumsfaktoren und Zytokine untersucht. Unbehandelte hMSZ als auch 
hMSZ die mit Lipopolysacchariden (LPS) behandelt wurden, wiesen eine Spender-
abhängige Variabilität auf. Um die Möglichkeit zu untersuchen, ob hMSZ ihr spezifisches 
Expressionsmuster nach Implantation in zerstörtes Rückenmarksgewebe ändern können, 
wurden hMSZ mit Homogenaten von gesundem sowie verletztem Rückenmark von Ratten 
ko-kultiviert. Um weiterhin feststellen zu können, ob eine solche Änderung gewebsspezifisch 
ist, wurden zusätzlich Homogenate von gesundem und geschädigtem Herzgewebe von 
Ratten verwendet. Keines der genannten Homogenate war in der Lage die individuellen 
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Muster der Wachstumsfaktor- und Zytokin-Expression zu verändern, was darauf schließen 
lässt, dass die individuellen Expressionsmuster der hMSZ nach Implantation in geschädigtes 
Rückenmark unverändert bleibt. Eine solche spenderabhängige Variabilität kann jedoch den 
Grad einer folgenden funktionellen Regeneration weitreichend beeinflussen und es muss in 
Betracht gezogen werden, dass manche Spenderproben nicht die geeigneten 
Wachstumsfaktor- und Zytokin-Expressionsmuster für eine optimale Geweberegeneration 
aufweisen. 
Ein Hauptaspekt der vorliegenden Dissertation war die Evaluation einer auf hMSZ-
basierenden Tissue Engineering Strategie, die orientiertes axonales Wachstum und 
funktionelle Geweberegeneration in einem experimentellen Tiermodell der akuten 
Rückenmarksverletzung fördert. Hierfür wurden von einem Kooperationspartner hMSZ mit 
grün fluoreszierendem Protein (GFP) transduziert, um eine Identifikation der transplantierten 
Zellen zu ermöglichen. Diese Zellen wurden in orientierten Kollagen-Trägermatierialien 
ausgesät und in Hemisektionen des thorakalen Rückenmarks implantiert. Schon nach 1 
Woche zeigten Tiere, die hMSZ-besiedelte Trägermaterialien implantiert bekamen, eine 
deutliche funktionelle Verbesserung im Vergleich zu den Kontrolltieren. Des Weiteren 
zeigten die Verhaltensanalysen eine signifikante funktionelle Verbesserung im Vergleich zu 
den Kontrolltieren 4 Wochen nach Implantation, aber ohne Signifikanz nach 8 Wochen. 
Immunhistochemische Untersuchungen belegten, dass nur eine geringe Anzahl der 
transplantierten hMSZ bis zum Ende von 8 Wochen nach Implantation überlebt hatten. 
Dennoch wiesen die Tiere, die hMSZ besiedelte Trägermaterialien erhalten hatten, eine 
erhöhte Anzahl regenerierter Axone sowie eine reduzierte astrozytische und 
inflammatorische Reaktion auf. Interessanterweise exprimierten die Spender-hMSZ 
Chondroitinsulfat-Proteoglycane (CSPG) und obwohl nur wenige lebende Zellen detektiert 
wurden, konnten CSPG Ablagerungen im gesamten Trägermaterial nachgewiesen werden. 
Folglich ist es sehr wahrscheinlich, dass die regenerativen Eigenschaften der hMSZ von der 
Expression von Wachstumsfaktoren, Zytokinen und extrazellulären Matrixmolekülen 
herrühren, die ihrerseits in der Lage sind ansässige und eindringende Zellen zu 
beeinflussen.  
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3. Introduction 
3.1 Definition and types of stem cells 
In recent years, interest in understanding the differentiation capabilities of stem cells and 
their potential use in the treatment of diseases and injuries has become a major focus in 
regenerative medicine. Stem cells are defined by two cardinal features: (i) they are capable 
of renewing themselves continuously and (ii) they have the ability to differentiate into a range 
of different cell types (1). These two criteria are fulfilled by cells derived from both embryonic 
and adult sources (Figure 3.1). Embryonic stem cells (ESC) are derived from the inner cell 
mass (ICM) of a blastocyst. These cells are capable of passing through progenitor and 
precursor stages to differentiate into all tissues of the three germ layers (i. e. mesoderm, 
endoderm, ectoderm), and have therefore been classified as pluripotent. Adult (or somatic) 
stem cells can be found in a variety of tissues, including bone marrow (2, 3), liver (4), skin 
(5), brain (6) and intestine (7). Such adult derived stem cells are more restricted in their 
differentiation potential and have been classified as multipotent. A well studied population 
of such multipotent stem cells is that of the haematopoietic stem cells (8). In addition to 
pluripotent and multipotent stem cells, a population of unipotent stem cells (differentiation 
capacity only towards a single cell type) also exists, for example the spermatogonial stem 
cells that can only differentiate into a single sperm cell lineage (9).  
The differentiation potential depends on the turnover of cells in a certain tissue, as well as 
the ability for repair following injury or disease (10, 11). Cell lineages with a high turnover are 
mostly generated from pluripotent or multipotent stem cells, while cells with a long lifespan 
are differentiated from more restricted stem cells. For example, fully differentiated blood cells 
have a relatively short lifespan and therefore need to be replenished continuously, whereas 
neurons of the central nervous system have a much longer lifespan (12). For this purpose, 
stem cells are located in environmental niches of a given tissue, where intrinsic and extrinsic 
mechanisms regulate self-renewal and differentiation (13, 14). The concept of a stem cell 
niche was first suggested by Schofield in 1978 and further supported by a variety of 
experiments (15, 16).  
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Figure 3.1: Genesis of stem cells and their plasticity. Totipotent stem cells are generated by the first 
three divisions of the fertilized egg. Further cell divisions form the blastocyst which contains pluripotent 
embryonic stem cells. Adult or somatic stem cells are more restricted in their differentiation potential and 
are classified as multipotent (i.e. haematopoietic) or unipotent (i.e. spermatogonial) stem cells. 
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For many years it was thought that multipotent adult stem cells could only differentiate into 
cell lineages relevant for the tissue in which they resided. However, more recent 
investigations have suggested that some populations of adult stem cells have the capacity to 
differentiate into lineages of cell types completely different from their tissue of origin. This 
ability has been termed transdifferentiation (or plasticity) and implies that such cells are 
capable of undergoing immense genetic reprogramming (17, 18). Although this phenomenon 
has aroused substantial excitement, many researchers remain sceptical about the issue and 
have proposed that such plasticity is merely the result of cell fusion. Clear evidence that 
such fusion events can indeed take place has been obtained from several in vitro co-culture 
experiments (19, 20). However, it has also become clear that these events occur at only low 
frequency. Therefore, three other explanations for plasticity are still in discussion: (1) 
multiple tissue-specific stem cells exist in different tissues, (2) veritable pluripotent stem cells 
exist in postnatal life, or (3) cells may undergo dedifferentiation and redifferentiation (21). 
Generally, it is assumed that the differentiation potential of a stem cell is dependent on its 
developmental stage, and that development is a unidirectional process (i.e. stem cells 
progressing through progenitor and precursor stages to fully differentiated and mature cell 
types (22)). During such unidirectional differentiation, it was believed that a switch from one 
lineage pathway to another could not be accomplished. However, some reports have 
suggested that this process may not be just unidirectional. It has been reported that some 
niches are capable of reverting progenitor cells back to a stem cell phenotype (23, 24). Such 
reversibility had previously been identified in amphibians (25, 26). Although stem cell 
research is no longer in its infancy, there are still many issues concerning the function of 
stem cells in health and disease that remain to be clarified. Nonetheless, their potential for 
application in future cell-based intervention strategies in regenerative medicine remains 
enormous. 
3.2 Mesenchymal stromal cells 
Mesenchymal stromal cells (MSC) were first described by Friedenstein et al. as a stromal 
support system for haematopoietic stem cells in the bone marrow (27). These cells can be 
readily isolated from bone marrow, due to their propensity to adhere to tissue culture plastic 
as compared to the other cell types present within the bone marrow aspirates. Through 
repeated media replacement, it is possible to remove non-adherent (i. e. non-MSC) cells. 
Alternatively, it is possible to isolate MSC by centrifugation through a Ficoll or Percoll density 
gradient solution (28). Nevertheless, MSC constitute only a very small fraction of cells 
obtained from the bone marrow aspirate (approximately one MSC per 105 cells) but their 
numbers can be expanded easily (28). Apart from bone marrow, MSC can also be isolated 
from other sources, such as adipose tissue (29), skeletal muscle (30), peripheral- (31) and 
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umbilical cord blood (32), as well as from amniotic fluid (33). MSC express a range of 
markers such as CD73, CD90 and CD105, but lack haematopoietic surface markers such as 
CD11b, CD14, CD19, CD34, CD45, CD79α, and HLA-DR, (34). Characteristically, MSC can 
readily differentiate into adipocytes, chondrocytes and osteocytes (3). However, in the last 
few years it has been suggested that, under certain culture conditions, MSC might be able to 
cross lineage boundaries which were until recently thought to be uncrossable. (Trans-) 
differentiation into ectodermal cell types, such as neural cells (35-37), as well as endodermal 
cell types, for example hepatocytes (38, 39), has been reported (Figure 3.2).  
 
 
 
Figure 3.2: Differentiation capacity of mesenchymal stromal cells. Mesenchymal stromal cells can 
differentiate into adipocytes, chondrocytes and osteocytes. Additionally, studies suggest the 
transdifferentiation potential of mesenchymal stromal cells into ectodermal (i.e. neurons and astrocytes) as 
wells as endodermal cell types (i.e. hepatocytes). 
 
Although the multipotent differentiation capacity of MSC has been well established, the in-
contravertible proof of their stem cell character is still lacking, since MSC are not a 
homogenous population of cells and only a few of these cells are able to generate fibroblast 
colonies (40). The term mesenchymal stem cell, may thus no longer be valid (41). 
 
3.3 Therapeutic potential of mesenchymal stromal cells in spinal cord injury 
Several therapeutic goals have been targeted by the cell transplantation approach to repair 
spinal cord injury (SCI): (i) bridging of cystic cavitation, (ii) replacement of dead cells, and (iii) 
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establishment of an environment which promotes axonal regeneration. A wide range of 
different strategies have been investigated, including transplantation of whole tissue pieces 
such as peripheral nerves (42), embryonic spinal cord tissue (43) or the transplantation of 
cell suspensions (as either purified- or mixed cell populations). Populations of cells chosen 
for promoting tissue repair following experimental SCI have included purified Schwann cells 
(44), olfactory ensheathing cells (OEC, (45)) and embryonic stem or progenitor cells (46, 
47). Adult stem or progenitor cells have also been investigated for their ability to promote 
tissue repair after SCI, amongst which MSC were suggested to be a promising candidates 
(48). Transplantation of adult stem- or progenitor cells should diminish ethical concerns in 
contrast to embryonic stem- or progenitor cells. Furthermore, the possibility of generating 
autologous cells avoids any complications due to rejection.  
In preclinical studies it was demonstrated that a delayed transplantation of rat MSC 
promotes functional improvement after injury to the spinal cord (49, 50). However, the 
mechanism for this improvement was not identified. Histological analysis displayed the 
survival of transplanted, BrdU-labelled cells, as well as an overall distribution of the MSC 
throughout the damaged tissue, indicating high migratory activity. Furthermore, some neural 
antigens, such as nestin, NeuN and the oligodendrocyte marker Rip have been identified in 
the transplanted cells (50). However, it has been reported that only NeuN was detectable in 
donor MSC (e. g. Hofstetter et al. (49)). Such (negative) findings regarding the 
transdifferentiation capacity of MSC in vitro and in vivo have also been described by others 
(51, 52). Interestingly, in the report of Hofstetter and colleagues, donor MSC were found to 
form longitudinally orientated columns within the lesion. Such columns were associated with 
nestin-postive host cells (that were suggested but not proven to be immature astrocytes), 
mature GFAP-positive astrocytes as well as 5HT- and neurofilament (NF)-positive axons. It 
was suggested that the most likely mechanism of improved function was by donor cell 
expression of a range of growth factors, cytokines and cell surface adhesion molecules that 
supported axon regeneration rather than by replacing lost glia or neurons (49).    
An indirect (or neuroprotective) mechanism of improved function was also later suggested 
following MSC transplantation into rat spinal cord contusion injuries (53). The donor MSC 
occupied the lesion cavity and contributed to the preservation of host tissue, in particular of 
host myelin. Similar to the reports of Hofstetter and colleagues (49), donor MSC were 
observed to form longitudinally orientated guidance structures which supported host axonal 
growth. This effect was presumably being supported by the release of growth factors (i.e. 
NGF, BDNF, vascular endothelial growth factor (VEGF) and hepatocyte growth factor 
(HGF)) from the donor cells (54, 55).  
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In contrast, Parr and colleagues could not detect any functional recovery after 
transplantation of eGFP-positive rat MSC into a model of mid-thoracic (T8-T9) spinal cord 
compression injury (56). Furthermore, immunohistochemistry revealed no detection of any 
neural-related markers within the transplanted cells, demonstrating that no neural 
differentiation had taken place. However, transplantation of MSC did result in a significant 
reduction in the maximal area of cavitation compared to the control group. 
As an alternative approach to the direct transplantation of donor cells into or close to the 
lesion site, MSC have been intravenously injected to assess their ability to “home” to 
pathological tissues following spinal cord compression injuries (57). Rat donor MSC were 
labelled with iron-oxide nanoparticles, enabling their migration to be tracked in vivo by 
magnetic resonance imaging. MSC injected one week after SCI migrated to the lesion site 
and induced a significant improvement of locomotor function by 35 days. Transplanted cells 
also induced a significant reduction of secondary tissue degeneration and a following 
increase in spared white and grey matter. A similar approach was applied to chronic 
compression injuries of the spinal cord (rats having been lesioned 4 months earlier). 
Although transplanted MSC had no effect on locomotor function in the chronic lesion model, 
a significant improvement of hindlimb sensitivity was detected (57). Histological analysis of 
the lesioned spinal cord tissue revealed no differences in the volume of white- and grey 
matter compared to the control animals. 
The potential of human donor MSC to induce functional recovery in SCI models of varying 
severity demonstrated a most pronounced effect in moderate contusion injuries (58). MSC-
transplantation directly into the lesion epicentre one week after injury resulted in a significant 
histological and behavioural improvement. No significant differences could be detected 
between the non-grafted, mildly contused animals and those that received MSC transplants. 
The severely contused animals were distinguished by a high mortality due to a poor health 
and complicating issues like infections and autophagia (58).  
Although the mechanism of improved function following MSC transplantation in rodent 
models of SCI is far from clear, the procedure has been proven to be safe. Transplantation 
of rhesus monkey MSC into spinal cord injured rhesus monkeys was therefore performed in 
an attempt to move the technology closer to the clinical domain (59). A T9-T10 contusion 
injury was induced and half of the animals received a delayed (2 week) implantation of 
“neurally pre-differentiated” MSC, the remaining control animals received vehicle injections. 
By 3 months after cell transplantation, the grafted animals demonstrated almost normal 
sensory responses and improved locomotion. Identification of donor cells revealed that 
approximately 10% expressed some neural-related antigens (e.g. NF, neuron-specific 
enolase (NSE) and glial fibrillary acidic protein (GFAP)). However, the nuclear marker 
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(Hoechst 33342) that was chosen for pre-labelling cells prior to transplantation is notoriously 
prone to leakage and transfer to host cells (60). Once again, the data concerning 
transdifferentiation remained uncertain. The functional improvement, however, was clear. 
Despite the uncertainties surrounding the mechanism(s) of functional improvement, other 
groups have moved the technology directly to clinical investigations and have reported case 
studies and even phase I clinical trials (61, 62). A case report was used to highlight the 
electrophysiological and functional improvement of two patients with established, chronic 
SCI (61). Autologous MSC were obtained through needle aspiration of iliac crest bone 
marrow. Co-cultivation of MSC with the patients’ autoimmune T (AT) cells was reported to 
induce transdifferentiation towards a neural stem cell-like phenotype (NSC) (63). Forty eight 
hours prior to the transplantation of the newly generated NSC, the patients received an 
intravenous infusion of AT cells to generate a controlled inflammatory micro-environment for 
the transdifferentiated NSC. The injection of NSC was subsequently performed by an 
infusion via the artery feeding the lesion site and the patients underwent physiotherapy. Both 
patients (one paraplegic, the other quadriplegic) in the study demonstrated an apparent 
improvement of sensory and motor function.  
Transplantation of autologous bone marrow mononuclear cells containing MSC into patients 
suffering from traumatic SCI and complete loss of motor and sensory function was 
investigated in a phase I clinical trial (62). In this trial, 20 patients received cell transplants 
between 10 days and 18 months post injury, either via trans-femoral catheterization of the 
arteria vertebralis or intravenously. Both application strategies were investigated in acute (10 
- 30 days post injury) and chronic patients (2 -17 months after SCI). Although phase I clinical 
trials are performed to evaluate clinical safety, investigations of motor and sensory function 
was also assessed in the grafted patients. An improvement of function was noted in 5/7 of 
the acute patients and 1/13 of the chronic patients. Most importantly, the progress of 11 of 
the patients could be followed up for more than two years, revealing no complications and 
allowing the confirmation of the safety of this intervention strategy.  
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3.4 Hypothesis and goals of the thesis 
The hypothesis to be tested in the present thesis is that the reported beneficial effect of MSC 
transplantation into spinal cord lesions is due to a paracrine mechanism rather than the 
doubtful transdifferentiation of MSC to neural phenotypes.  
Since transdifferentiation of MSC into cells of the neural lineage has been controversially 
discussed, the origin of these different opinions will be investigated. Therefore, the basal 
expression of neural-related markers in untreated hMSC from different donors will be 
determined.  
MSC are of substantial importance in several clinical applications and a defined cultivation 
protocol for clinical use is needed. Conventially, laboratory MSC expansion has been 
performed in culture medium supplemented with 10% serum. Since animal- or donor-derived 
sera might transfer infectious agents or might lead to a host immune response, a 
standardized serum-free cultivation protocol for the expansion of MSC will be developed. 
Increasing evidence suggests that the regenerative properties of MSC are due to paracrine 
effects. Indeed, MSC are capable of secreting a variety of growth factors and cytokines 
which may enhance the re-growth of axons. One question that will be addressed in the 
present thesis is the possibility that MSC might change their growth factor and cytokine 
expression patterns when implanted into the injured spinal cord. Therefore, hMSC will be co-
cultivated with tissue extracts of normal or injured rat spinal cord. To evaluate the possibility 
that such an expression change may be due to tissue-specific effects, extracts of normal or 
injured rat heart will also be used as tissue controls. 
Although MSC have been demonstrated to have beneficial effects in promoting spinal cord 
repair, the majority of the studies have performed compression/contusion injuries followed 
by direct or delayed injection of MSC. The main aim of the present thesis is to investigate 
the regenerative properties of hMSC in an experimental model of acute penetrating spinal 
cord injuries followed by direct implantation of an hMSC-seeded, orientated microporous 3D 
scaffold. For quantitative evaluation of the functional improvements, a number of behavioural 
and histological methods will be applied and correlated. 
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4. Neural differentiation potential of human bone marrow-
derived mesenchymal stromal cells: misleading marker 
gene expression 
4.1 Abstract 
In contrast to pluripotent embryonic stem cells, adult stem cells have been considered to be 
multipotent, being somewhat more restricted in their differentiation capacity and only giving 
rise to cell types related to their tissue of origin. Several studies, however, have reported that 
bone marrow-derived MSC are capable of transdifferentiating to neural cell types, effectively 
crossing normal lineage restriction boundaries. Such reports have been based on the 
detection of neural-related proteins by the differentiated MSC. In order to assess the 
potential of human adult MSC to undergo true differentiation to a neural lineage and to 
determine the degree of homogeneity between donor samples, we have used RT-PCR and 
immunocytochemistry to investigate the basal expression of a range of neural related 
mRNAs and proteins in populations of non-differentiated MSC obtained from 4 donors. 
The expression analysis revealed that several of the commonly used marker genes from 
other studies like nestin, Enolase2 and microtubule associated protein 1b (MAP1b) are 
already expressed by undifferentiated human MSC. Furthermore, mRNA for some of the 
neural-related transcription factors, e.g. Engrailed-1 and Nurr1 were also strongly 
expressed. However, several other neural-related mRNAs (e.g. DRD2, enolase2, NFL and 
MBP) could be identified, but not in all donor samples. Similarly, synaptic vesicle-related 
mRNA, STX1A could only be detected in 2 of the 4 undifferentiated donor hMSC samples. 
More significantly, each donor sample revealed a unique expression pattern, demonstrating 
a significant variation of marker expression.  
The present study highlights the existence of an inter-donor variability of expression of 
neural-related markers in human MSC samples that has not previously been described. This 
donor-related heterogeneity might influence the reproducibility of transdifferentiation 
protocols as well as contributing to the ongoing controversy about differentiation capacities 
of MSC. Therefore, further studies need to consider the differences between donor samples 
prior to any treatment as well as the possibility of harvesting donor cells that may be 
inappropriate for transplantation strategies. 
4.2 Introduction 
MSC, often termed mesenchymal stem cells, may be isolated from bone marrow, adipose 
and other tissues.  They adhere strongly to tissue culture plastic and are capable of 
multipotent differentiation that can be demonstrated in vitro. MSC can differentiate into 
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osteoblasts, chondroblasts, adipocytes and myoblasts (reviewed in (3)). Since the survival 
and migration of human MSC (hMSC) grafted into rat brains was demonstrated (64), the 
possibility that such cells might act as suitable tools for promoting central nervous system 
(CNS) repair has been raised. This notion was further strengthened by the report that murine 
MSC may differentiate into mature astrocytes after implantation into neonatal mouse brains 
(65). Donor MSC have also been reported to give rise to neuronal phenotypes in adult mice 
brains after transplantation (66, 67). During the last six years, there have been many reports 
describing in vitro neural transdifferentiation of MSC derived from a range of different 
species (e.g. human, mouse, rat). All protocols that have been used for such investigations 
can be divided into three broad categories: i.e. those using (i) chemical compounds (37, 68-
71), (ii) growth factors (72-75), or (iii) neurosphere-like cultivation (76-81). Furthermore, 
combinations of these different protocols have also been reported to induce neural 
differentiation (82, 83). Such reports of in vitro neural transdifferentiation by MSC derived 
from experimental animal- or human sources have been based on the detection of neural-
related mRNA as well as proteins by the treated cells. In the present investigation, RT-PCR 
and immunocytochemistry were used to demonstrate the basal expression of several of the 
commonly used marker genes or proteins by undifferentiated human MSC. The data 
obtained by this study revealed a substantial degree of heterogeneity of the basal 
expression of neural-related genes that had not previously been described. 
4.3 Materials and methods 
4.3.1 Sampling of human MSC 
Bone marrow was aspirated from patients during hip joint replacement following informed 
consent, according to local ethical board approval of the University Hospital, Aachen. 
4.3.2 Isolation and cultivation of human MSC 
Bone marrow aspirates were diluted 1:5 in mesenchymal stem cell growth medium 
(MSCGM, Lonza, Vervieres, Belgium) and immediately seeded into polystyrene plastic 75 
cm2 tissue culture flasks at 37°C in 5% humidified CO2. After seven days, non-adherent cells 
were removed by media replacement and adherent cells were expanded in MSCGM. Media 
exchange was performed every 3-4 days until cells reached 80% confluence. For passaging, 
the cells were detached with trypsin/EDTA solution (Lonza, Vervieres, Belgium) and re-
seeded with a density of 4000 cells/cm2.  
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4.3.3 Characterization of isolated human MSC 
For characterization of human MSC, three criteria were used: i) adherence to tissue culture 
plastic, ii) specific surface antigen expression, and iii) multipotent differentiation potential 
(34). The morphology of plastic adherent cells was monitored using an inverse microscope 
(DM IL Invers, Leica, Wetzlar, Germany). To detect specific surface antigens, cells were 
detached and fixed with 4% paraformaldehyde for 20 min. After washing with 0.1 M 
phosphate-buffered saline (PBS), cells were incubated in blocking solution (20% FBS in 
PBS, Biowest, Nuaille, France) for 20 min. After washing with PBS, the cell pellets (250,000 
per antibody) were resuspended in 100 µl PBS, 2 µl primary antibody was added and 
incubated for 30 min. Monoclonal primary antibodies recognizing surface markers CD11b 
(Invitrogen, Carlsbad, USA), CD19, CD34, CD45, CD73, CD90 (Becton Dickinson, San 
Jose, USA), CD105 (Invitrogen)  and HLA-DR (Abcam, Cambridge, UK) were used. After 
three washing steps with PBS, 2 µl of the secondary antibody (Alexa-488 conjugated goat 
anti-mouse, Invitrogen) was incubated in 100 µl PBS for 30 min in the dark. After two final 
washing steps, the cells were re-suspended in 400 µl PBS and analyzed using a 
FACSCalibur and FACSCalibur software (Becton Dickinson).      
Multipotency was monitored by in vitro differentiation of MSC to adipogenic, chondrogenic 
and osteogenic lineages according to Pittenger et al. (28). To induce adipogenesis, cells 
were cultivated in adipogenic induction medium (DMEM (Lonza, Vervieres, Belgium) with 
10% FCS, 0.5 µM dexamethasone, 0.5 µM indomethacin, and 0.5 mM isobutyl-methyl-
xanthine (all Sigma, Steinheim, Germany)). Medium was changed every 3 days for 3 weeks. 
To visualise lipid droplets, Oil Red O staining (Sigma) was used as a histologic stain.  
Osteogenic differentiation was induced by cultivation of MSC in osteogenic induction 
medium (DMEM with 10% FCS , 20 nM sodium β-glycerophosphate, 1 nM dexamethasone, 
and 50 µg/ml 1-ascorbic acid 2-phosphate, all purchased form Sigma). Medium was 
changed every 3 days for 3 weeks. Osteogenic differentiation was visualised by Alizarin-
Red-S staining (Sigma) of matrix mineralization associated with osteoblasts (according to 
the method of (84)).  
For chondrogenic differentiation, 2.5 x 105 cells were centrifuged to obtain cell pellets. These 
pellets were induced with serum free induction media (DMEM) containing 100 nM 
dexamethasone, 0.17 mM 1-ascorbic acid 2-phosphate, 100 µg/ml sodium pyruvate, 40 
µg/ml proline (all Sigma), and 1 % ITS-Plus (Becton Dickinson). TGF-β3 (CellSystems, 
Sankt Katharinen, Germany) was added in a concentration of 10 ng/ml at each medium 
exchange. After 21 days, pellets were fixed with PFA and paraffin embedded. Thin sections 
were stained with Toluidine blue (Sigma) to show metachromatic staining which is 
characteristic of cartilage (84, 85).  
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4.3.4 Gene expression analysis 
RNA was isolated using the RNeasy Mini Kit (Qiagen, Hilden, Germany) according the 
manufacturers protocol. The integrity of isolated RNA was evaluated using the 2100 
bioanalyzer (Agilent Technologies, Palo Alto, USA). For PCR analysis 2 µg RNA was 
reverse transcribed using Omniscript Reverse Transcriptase (Qiagen, Hilden, Germany) 
according the manufacturers protocol using oligo-d(T) primers and random hexamers. 
Commercially available samples of human adult and fetal brain total RNA were used as 
positive controls (Ambion, Austin, USA and Clontech-Takara Bio Europe, Saint-Germain-en-
Laye, France). For amplification of target genes, 0.2 units Taq polymerase (Amersham 
Biosciences, New York, USA) were used with a standard PCR program (denaturation: 10 
sec at 96°C; primer hybridisation: 2 min at various target specifc temperatures, see table 1; 
elongation: 2 min at 72°C).  
Table 4.1: Primer sequences and PCR conditions 
Primer Forward (5´- 3´) Reverse (5´- 3´) Hybridization  Cycles Amplicon  
      
temperature 
(°C)   size (bp) 
ASCL1 aag caa gtc aag cga cag cg agtcgt tgg agt agt tgg gg  62 35 352 
Bag1 tca ccc aca gca at gaga ag cag aaa acc ctg ctg gat tc  66 30 344 
DRD2 tca tcg ctg tca tcg tct tcg  gat gga gat cat gac ggt gac 65 40 344 
Engrailed-1 agc cac agg cat caa gaa cg  cac ctg tcc gag tct ttc tc 65 40 303 
Enolase2 ggc aaa ggt gtc ctg aa gg c  gtg ccg gcc ttc aac gtg at 67 30 284 
GAPDH tga agg tcg gag tca acg gat ttg gt  cat gtg ggc cat gag gtc cac cac  62 30 983 
GFAP gtg gta ccg ctc caa gtt tgc ag  aat ggt gat ccg gtt ctc ctc  59 40 373 
MAP1B act gca gga cca gga act ac cag tgt cac ctg cat gtt gc  67 25 255 
MAPT agc tct ggt gaa cct cca aaa tc  cat cca tca taa acc agg agg tg 58 40 361, 454 
MBP cct ggc cac agc aag tac ggg agc cgt agt gag cag t  61 35 251 
Nestin gcg ttg gaa cag agg ttg gag gca cag gtg tct caa ggg tag  65 30 385 
NEUROD6 ctg aga atc ggc aag aga cc  ctg cac agt aat gca tgc cg 62 35 433 
NFH tga aca cag acg cta tgc gct cag cac ctt tat gtg agt gga cac aga g  58 35 398 
NFL acc aac gag aag caa gcg ctc  cat cag cgc tat gca gga cac 59 35 590 
NFM aaa gac atc gag gag gcg tc  cgc tgc gta cag aaa act cc  61 35 592 
Nurr1 aag gct tct tta agc gca cag  cga tta gca tac agg tcc aac  55 25 518 
S100ß gga gac aag cac aag ctg aag agc tac aac acg gct gga aag 63 30 322 
STX1A atc gca gag aac gtg gag gag  agc gtg gag tgc tgt gtc ttc 67 30 230 
SYP ggt gct gca atg ggt ctt cgc  aag ccg aac acc acc gag gtg 59 35 537 
TH atc cac cat cta gag acc cg tcc ccg ttc tgc tta cac ag  63 40 824 
 
PCR products were analyzed by electrophoresis on a 1.7% agarose gel and visualized with 
0.5 µg/ml ethidium bromide. PCR conditions were established using adult and fetal brain 
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cDNA and best results from at least two independent experiments were chosen for 
expression analysis of hMSC. Expression of each marker was monitored by testing cDNA of 
all four donors using the same master mix, PCR condition and gel electrophoresis. 
 
4.3.5 Immunocytochemistry 
The hMSC were seeded at a relatively low density to allow the clear identification of 
individual cells for quantification. After removal of the media and washing in 0.1 M PBS, cells 
were fixed with 4 % paraformaldehyde in PBS for 30 min. Afterwards, the samples were 
washed three times with PBS and non-specific binding sites blocked by a 1 hour incubation 
in PBS containing 3 % normal goat serum (Sigma), 1 % bovine serum albumin (BSA, 
fraction 5, Serva, Heidelberg, Germany) and 1 % Triton X-100 (Sigma). The primary 
antibodies anti-enolase2 (monoclonal, Dako M0873; 1:500), anti-MAP1b (monoclonal, 
Sigma M4528; 1:500), anti-Nurr1 (monoclonal, Abnova H00004929-M07; 1:200) and anti-
nestin (polyclonal, Chemicon AB5922; 1:200) were diluted in PBS containing 1% BSA and 
incubated at room temperature overnight. The secondary antibodies, goat-anti-mouse Alexa 
594 (1:500, Invitrogen) and goat-anti-rabbit Alexa 488 (1:500, Invitrogen), were also diluted 
PBS containing 1% BSA and incubated for 2.5 hours at room temperature. Finally, nuclei 
were stained with diamidinophenylindole (DAPI, 1:1000, Roche), cover-slipped with 
Fluoroprep (bioMerieux, Marcy l’Etoile, France) and observed using a Leica DM RX 
microscope (Leica, Wetzlar, Germany) with 20x objective. Omission of primary antibodies 
served as negative control and resulted in no detectable staining. Immunocytochemistry of 
cells obtained from three different donors was performed on 2 separate occasions. The 
proportion of cells immunoreactive for a particular antigen was quantified by counting 100 
cells per donor sample. To achieve this, 10 randomly chosen, non-overlapping microscopic 
fields (each 577 µm x 465 µm) distributed evenly across the whole sample were 
photographed to provide representative images of the stained and non-stained cells. The 10 
fields were believed to be representative of whole donor samples because the 
immunocytochemistry revealed that there was no heterogeneity of the distributions of the 
stained and non-stained cells - i.e. there were no clusters of stained cells or non-stained 
cells. 
4.4 Results  
4.4.1 Characterization of human MSC 
Isolated hMSC were characterized by three criteria: (i) adherence to tissue culture plastic, (ii) 
specific surface antigen expression, and (iii) multipotent differentiation as defined by the 
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Mesenchymal and Tissue Stem Cell Committee of the International Society for Cellular 
Therapy (34).  
Fluorescent activated cell sorting (FACS) analysis demonstrated that the expanded, plastic 
adherent cells used in the present investigation were positive for the surface markers CD73, 
CD90 and CD105, but negative for CD11b, CD19, CD34, CD45 and HLA-DR (Figure 4.1).  
 
 
Figure 4.1: Surface marker expression of human MSC. FACS analysis of the immunophenotypic surface 
profile for CD11b, CD19, CD34, CD45, CD73, CD90, CD105 and HLA-DR of isolated hMSC. Red histograms 
represent the fluorescence from negative-control cells incubated with only secondary antibody; black 
histograms represent the counts of cells incubated with the relevant primary antibody. The logarithm on the X-
axis (FL1-H channel) represents the intensity of the fluorescent signal and the number of cells is given on the 
Y-axis. HMSC isolated in this study were positive for the markers CD73, CD90 and CD105, but negative for 
CD11b, CD19, CD34, CD45 and HLA-DR according to the criteria for MSC. 
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To demonstrate their multipotent potential, MSC were differentiated to adipocytes, 
chondrocytes and osteocytes according to published protocols (28). Lipid vacuoles in 
differentiated adipocytes were visualized with Oil Red O (Figure 4.2A). However, not all cells 
demonstrated the same degree of staining. Induction of chondrogenic differentiation was 
performed in cell pellets which developed a proteoglycan-rich extracellular matrix. Thin 
sections of these pellets were stained with Toluidine Blue (Figure 4.2B), demonstrating a 
metachromatic staining that was characteristic of cartilage matrix (85). Osteogenic 
differentiation resulted in an immense production of mineral deposits that were stained with 
Alizarin-Red-S (Figure 4.2C). Thus, the cells used in this study fulfilled all criteria to be 
defined as MSC. 
 
Figure 4.2: Differentiation capacity of hMSC. The hMSC were cultivated for 21 days in differentiation 
media to show multi-potentiality. (A) Adipogenic differentiation resulted in the formation of lipid vacuoles 
which were stained with Oil Red O; (B) Thin sections of chondrogenic differentiated hMSC-derived cell pellets 
were stained with Toluidine Blue, demonstrating a highly enriched extracellular matrix; (C) Alician Red 
staining of hMSC induced to osteocytes revealed an immense mineral deposition. 
 
4.4.2 Neural marker expression by undifferentiated human MSC 
The neural specific RNA transcripts, obtained from hMSC of four different donors, were 
categorized into four sub-groups: (i) neuronal markers, (ii) glial markers, (iii) neural related 
transcription factors and (iv) others (Figure 4.3, table 4.2). For every marker, both adult and 
fetal human brain extracts were used as positive controls. 
Neuronal markers: One of the neuronal markers investigated was dopamine receptor D2 
(DRD2), a marker for dopaminergic neurons (86), which was moderately expressed by three 
donors (donors 1, 2 and 4). Transcripts for enolase2 (or neuron-specific enolase, NSE), 
normally found in mature neurons and in cells of neuronal origin (87), were also found in 
human MSC (donor 2 moderate, donors 3 and 4 weak).  Microtubule-associated protein 1b 
(MAP1b), that is suggested to play an important cytoskeletal role in development and 
function of the nervous system (88), was strongly detected in donors 2 to 4 as well as 
moderately in donor 1. Other widely used markers for neurons are the neurofilaments (NF). 
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The expression of NFH (heavy), NFM (medium) and NFL (light) in human MSC was 
analyzed in the present study. Low levels of transcripts for NFL could only be detected in 
donors 1 and 4, but moderate levels were found in donor 2. The syntaxin (STX1A) functions 
in the fusion of synaptic vesicles with the synaptic membrane of neurons (89). However, a 
moderate amount of STX1A was also detected in the undifferentiated MSC of donor 3 and 4. 
Another synaptic vesicle-related protein, synaptophysin (SYP) (90), was only slightly 
detectable in donors 2 to 4. The expression of tyrosine hydroxylase (TH), a neurotransmitter-
related enzyme in catecholaminergic neurons, was also only weakly detectable in donor 2. 
No expression of mRNA for the axonal microtubule-associated protein tau (MAPT, (91)) 
could be observed (for an overview of the case-by-case expression of the markers genes, 
see Table 4.1).    
Glial markers analyzed in this study were glial fibrillary acidic protein (GFAP) (92), myelin 
basic protein (MBP) (93) and the calcium binding protein, S100β (94). None of the hMSC 
were found to express S100β or GFAP, an intermediate filament protein that is normally 
expressed by astrocytes and Schwann cells. However, 3 of the hMSC population (donors 2-
4) were found to express low levels of mRNA for MBP, a major myelin associated protein.  
Neural-related transcription factors. Transcripts for achaete-scute complex homolog 1 
(ASCL1, also known as Mash1), a transcription factor that plays a role in neuronal 
commitment and differentiation and in the generation of olfactory and autonomic neurons 
(95), could not be detected in any of the donor cells. Furthermore, none of the donor cells 
expressed mRNA for neurogenic differentiation 6 (NEUROD6), a factor suggested to be 
involved in the development and maintenance of the mammalian nervous system (96). 
However, the expression of the homeobox protein Engrailed-1 (important in the formation of 
interneurons (97) as well as in the regionalization of the developing brain (98)) and Nurr1 
(involved in the function of dopaminergic neurons (99)), were detected at moderate  (donor 
3) and strong levels (donors 1, 2 and 4).  
Others: The transcripts investigated in this category were Bag1, nestin and also GAPDH 
(which served as an internal control). Bag1, which has anti-apoptotic functions in a variety of 
cell types and plays an essential role in the survival of differentiated neurons (100), was 
highly expressed in all donor samples. The intermediate filament protein nestin, was initially 
identified as a marker for neural stem cells (101), but has since been found to have a much 
broader expression in a range of cell types and tissues (102-107). Transcripts for nestin 
were also detected in all human donor MSC samples, however, there were clear differences 
in the intensity of the signal; MSC derived from donor 2 being much stronger than that from 
donors 1, 3 and 4.  
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Figure 4.3: Neural marker expression of human MSCs. Neural marker transcripts of four different donors 
were amplified by RT-PCR. Water served as negative control and commercially obtained adult (a) or fetal (f) 
brain cDNA was used as positive control. GAPDH was used as standard. 
 
The commercially available samples of total RNA that had been generated from adult and 
fetal human brain samples showed developmentally related changes in the intensity of 
expression for certain mRNAs, e.g. stronger bands for the neuronal markers Enolase2, NFH, 
SYP, the glial markers MBP and S100β, and the transcription factor Engrailed-1 were fall 
elevated in control adult samples. However, weaker bands for MAP1b, nestin and the 
transcription factors ASCL1 and NEUROD6 were found in adult control samples. No major 
differences in the intensity of bands between control adult and fetal brain samples could be 
found for the other transcripts (i.e. DRD2, NFM, NFL, STX1A, TH, GFAP, Nurr1 and Bag1). 
The differences in mRNA transcripts resemble the expected shifts in the intensity of 
expression during the development of the nervous system. The transcription factors of the 
basic helix-loop-helix family ASCL1 and NEUROD6 are expressed in neuronal progenitors 
(108, 109) and the cytoskeletal constituents nestin and MAP1b were expressed at higher 
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levels in the control fetal samples. On the contrary, Enolase2 (87), NFH (110), SYP (90), 
MBP (93) and S100β (111) are expressed by more mature cells, reflecting their higher level 
of expression in the control adult samples. Although the transcription factor Engrailed-1 
plays a role in the formation of interneurons as well as in the regionalization of the 
developing brain (98), it is possible that the developmental stage from which the control fetal 
sample was obtained had already passed the time point for expression. Alternatively, 
expression of the transcript is only found in a fraction of cells and is diminished in total brain 
mRNA extraction. The faint Engrailed-1 band detected in the adult samples may have 
reflected its anti-apoptotic role in mature neurons (112).  
Table 4.2: Summary of neural-related marker expression. PCR transcript expression was defined as 
strong (+++), moderate (++), weak (+) or not detectable (-). 
Marker Donor 1 Donor 2 Donor 3 Donor 4 
DRD2 ++ ++ - ++ 
Enolase 2 - ++ + + 
MAPT - - - - 
MAP1b ++ +++ +++ +++ 
NFH - - - - 
NFM - - - - 
NFL + ++ - + 
STX1A - - ++ ++ 
SYP - + + + 
TH - + - - 
GFAP - - - - 
MBP - + + + 
S100β - - - - 
ASCL1 - - - - 
Engrailed-1 +++ +++ ++ +++ 
NEUROD6 - - - - 
Nurr1 +++ +++ ++ +++ 
Bag1 +++ +++ +++ +++ 
Nestin ++ +++ ++ ++ 
GAPDH +++ +++ +++ +++ 
 
 
4.4.3 Immunocytochemical detection of neural marker proteins by 
undifferentiated human MSC 
In addition to RT-PCR, a number of non-differentiated donor hMSC samples were chosen 
for immunocytochemical analysis. Staining of Enolase2 revealed a cytoplasmic distribution 
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(Figure 4.4A). A cytoskeletal staining was observed with antibodies against MAP1b (Figure 
4.4B) and nestin (Figure 4.4D). However, staining for Nurr1 was detected at different 
intensities and revealed a cytoplasmic distribution (Figure 3.4C). Quantification of 
immunocytochemical staining from three donors (Figure 4.4E) revealed that Enolase2 
expression was found in 59 ± 27.1% of all cells, Map1b expression was found in 66.7 ± 
12.2% of all cells, and Nurr1 expression was found in 46.3 ± 10.8% of the cells expressed. 
Nestin expression was found to be present in all cells of the three donors analyzed. Thus, 
this data demonstrates that both protein and mRNAs of a range of neurally-related markers 
is already expressed by non-differentiated hMSC. 
 
Figure 4.4: Expression of neural related proteins. Immunofluorescence for neural related proteins in 
undifferentiated hMSCs. (A) Enolase2, (B) MAP1b, (C) Nurr1 and (D) nestin. Staining revealed cytoplasmic 
distribution of Enolase2 and Nurr1, whereas the staining of MAP1b and nestin was cytoskeletal. Scale bar 
100 µm. (E) Quantification of the percentage of stained cells from three different donors revealed following 
data: Enolase2 expression was found in 59% ± 27.1% of all cells, 66.7% ± 12.2% Map1b positive cells, and 
46.3% ± 10.8% of the cells expressed Nurr1. Nestin expression was found to be present in all cells analyzed. 
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4.5 Discussion  
The potential of adult MSC to transdifferentiate into neural cell types has aroused great 
interest in research. Such a capacity opens extensive possibilities for autologous therapeutic 
treatments in a variety of neurological disorders. However, clear and unequivocal data 
regarding differentiation needs to be generated to provide a solid foundation for further 
studies. In the present investigation, undifferentiated hMSC were found to express a number 
of neural-related genes (albeit at rather low levels for some mRNAs). Significantly, it became 
clear that there was considerable donor-related  heterogeneity in the expression pattern of 
the hMSC populations, even though the criteria for isolation and identification (as set out by 
the Mesenchymal and Tissue Stem Cell Committee of the International Society for Cellular 
Therapy (34)) were followed. It is possible that such donor heterogeneity might be 
responsible for the variable degree of success reported by a number of research groups in 
their ability to transdifferentiate hMSC to a neural phenotype. 
One of the first descriptions of neural differentiation by hMSC reported the detection of 
nestin and GFAP after differentiation, but importantly failed to report the pre-differentiated 
phenotype of the cells (72). This same oversight has also occurred in a most recent 
publication demonstrating the generation of neural cell types from human bone marrow-
derived MSC (113). Neurospheres derived from human MSC were shown 
immunocytochemically to express nestin and Musashi-1, however, the basal expression 
profile of the MSC was not reported. Rapid morphological changes of rat MSC have also 
been reported to be associated with the detection of enolase2 and NFM (amongst other 
markers (37)). However, the non-treated, control cells were not analyzed and the rapid 
morphological changes aroused great skepticism because they did not reflect normal 
developmental processes (114). Such changes were later demonstrated to be due to the 
breakdown of the actin cytoskeleton (115).  
Previous attempts to identify the basal expression pattern of undifferentiated human MSC 
using serial analysis of gene expression (SAGE) has revealed the presence of mRNA not 
only characteristic for mesenchymal cells but also endothelial, epithelial and neuronal 
lineages (116). Neural related mRNAs found to be amongst the 50 most abundant gene 
products expressed included high molecular weight neurofilament (NFH), the high affinity 
nerve growth factor receptor (TrkA) and glial derived nexin 1 alpha. However, in stark 
contrast, NFH was undetectable in all donor hMSC samples of the present investigation. 
This observation likely reflects the high degree of donor sample heterogeneity mentioned 
earlier.  
Heterogeneity of gene expression by rat and human MSC has also reported following RT-
PCR of cell populations and clonal cell lines, revealing mesodermal, germinal, endodermal 
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and ectodermal expression patterns (117, 118). Neurally related transcripts expressed by rat 
MSC included NMDA receptor sub-units, syntaxin, amyloid precursor protein, and both rat 
and human MSC were reported to express GFAP and NeuroD mRNA (117, 118). Both of 
these transcript were absent in all of the samples used in the present investigation. 
However, Syntaxin 1A was weakly expressed in 2 of the human samples but was negative in 
the remaining 2 donor samples, once again highlighting the substantial inter-donor 
variability.  
In the present investigation, the expression of nestin mRNA could be found in all donor 
samples of undifferentiated hMSC. Nestin was originally identified as an intermediate 
filament protein expressed by neural stem cells (119). Recent reports using rat MSC have 
described undifferentiated MSC as being nestin-negative, but that expression increased 
progressively with increasingly higher passage numbers (76). The acquisition of nestin 
expression by the higher passage number MSC has been suggested to be an important 
stage in the ability of the cells to form spheres and subsequently undergo neural 
differentiation (76). It is possible that such progressive increase of nestin expression may 
reflect the culture conditions selecting for – and enhancing the proliferation of a sub-
population of nestin-positive cells. The presence of such sub-populations of stem cells or 
progenitors within MSC may contribute to the high degree of heterogeneity reported by 
others (116-118, 120, 121). Indeed both intrinsic plasticity of MSC and contamination by 
stem cells from other sources (neural crest-derived stem cells) have been suggested to be 
contributory mechanism to the apparent switch to a neural phenotype by MSC (118, 122). 
Although recent publications have demonstrated the expression of a number of neural-
related genes in non-differentiated population or clones of MSC, the degree of donor 
variability has, until now, remained unclear.  
Transplantation of undifferentiated MSC into experimental models of CNS injury has clearly 
demonstrated improved motor and sensory function (49, 53, 57), and in a phase I clinical 
study, transplantation was proven to be safe (62, 123). Following engraftment, donor MSC 
were reported to be associated with a range of neuronal and glial markers suggesting the 
spontaneous differentiation of the grafted cells in vivo (67, 124-126). Since it was shown, 
that the spontaneous differentiation of grafted cells occurs only in few cells (124), other 
reasons for inducing a beneficial outcome should be considered. An on-going discussion 
revolves around the possible improvement in function being an outcome of cell fusion events 
between donor MSC with host cells (19, 20). However, cell fusion also occurs at only a very 
low frequency (19) and it has been described that neural differentiation can occur without 
this phenomenon (76, 80). An alternative, and possibly more likely, mechanism for improved 
function after implantation of MSC may be due to the local release of growth factors (55, 
127). It has been shown that undifferentiated MSC express a range of growth factors 
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including neurotrophin-3 (NT-3), brain-derived neurotrophic factor (BDNF), glial-derived 
neurotrophic factor (GDNF), nerve growth factor (NGF), vascular endothelial growth factor 
(VEGF), hepatocyte growth factor (HGF) (128), ciliary neurotrophic factor (CNTF) and basic 
fibroblast growth factors (bFGF) (127, 129, 130). These factors could certainly play a role in 
several processes, including neurogenesis, neuroprotection, vascularisation and scar 
inhibition as it was already demonstrated for VEGF (131). Such donor heterogeneity was 
also reported by others for growth factor secretion by hMSC. Transplantation of cells was 
found to promote a variable, donor-dependent degree of axon growth and functional 
recovery (127). Furthermore, it is possible that donor MSC may also influence axonal or 
tissue regeneration in- and around the host lesion site by providing an array of growth-
supporting extracellular matrix molecules, including fibronectin, collagens, laminin, 
hyaluronan and proteoglycans. These molecules are involved in migration, cell survival, cell 
proliferation and cell differentiation (reviewed in (132)) and a change in their local 
concentrations may influence endogenous neural stem cells (130).  
4.6 Conclusion 
The ability of MSC, in particular human MSC, to generate neural-related cell types for future 
transplantation-based intervention strategies has become a topic of considerable 
controversy. A number of possible mechanisms have been suggested to explain such 
cellular behaviour, including true transdifferentiation, the presence of multiply-primed stem 
cells capable of differentiating into a number of lineages, contamination by neural crest-
derived stem cells and tissue culture artefacts. The present investigation supports the 
contention that MSC selected on the basis of plastic adherence, multipotency and FACS 
analysis are highly heterogeneous populations of cells. All donor samples investigated in the 
present demonstrated expression patterns that were different from each other. Such inter-
donor variability regarding the expression of neural-related genes has not been previously 
described, but supports the heterogeneity of hMSC reported by others. It is possible that 
such inter-individual variability may affect the ability of donated cells to respond to particular 
tissue culture conditions. It should therefore be considered that not all donated MSC may be 
appropriate for future autograft cell transplantation strategies.   
 
EXPANSION OF HUMAN BONE MARROW-DERIVED MESENCHYMAL STROMAL CELLS: SERUM-
REDUCED MEDIUM IS BETTER THAN CONVENTIONAL MEDIUM 
 
27
 
5. Expansion of human bone marrow-derived 
mesenchymal stromal cells: serum-reduced medium is 
better than conventional medium  
5.1 Abstract 
HMSC are of enormous interest for various clinical applications. For the expansion of 
isolated hMSC to relevant numbers for clinical applications, 10% FBS supplemented 
medium is commonly used. The main critical disadvantage of FBS is the possibility of the 
transmission of infectious agents as well as the possibility of immune rejection of the 
transplanted cells in response to the bovine serum. Therefore, we tested a commercially 
available medium, Panserin 401, which was specifically developed for serum-free cell 
cultivation. HMSC were isolated from bone marrow and expanded in either DMEM or 
Panserin 401 alone, or combined with FBS (2% or 10%), with or without supplementary 
growth factors. Cell proliferation and cytotoxicity were monitored twice a week for three 
weeks.  
No proliferation was observed in any of the serum-free media. However, DMEM/10% FBS 
(the conventional culture medium for hMSC), and DMEM/2% FBS with growth factors 
revealed moderate proliferation. Interestingly, the best proliferation was obtained using 
Panserin 401 supplemented with 2% FBS and growth factors (as well as with 10% FBS). 
Analysis of cell growth in Panserin 401 supplemented with 2% FBS-only or with growth 
factors-only revealed no proliferation, demonstrating the necessity of the combination of 2% 
FBS and growth factors. Efficient isolation and expansion of hMSC from cancellous bone 
could also be performed using Panserin 401 with 2% FBS and growth factors. Furthermore, 
these isolated cultures maintained multipotency, as demonstrated by adipogenic and 
osteogenic differentiation.  
5.2 Introduction 
HMSC are of great interest in a variety of clinical applications. These multipotent cells are 
capable of differentiating into various mesenchymal cell-types, such as adipocytes, 
osteocytes, chondrocytes and myoblasts (3). Human MSC represent a small proportion 
(0.01-0.02%) of bone marrow cells (133) which can readily be  isolated from the bone 
marrow and adipose tissue for expansion in vitro (28, 29). Cell-based transplantation 
strategies of autologous and allogenic hMSC have been assessed in clinical trials for a 
variety of diseases, including acute myocardial infarction (134), multiple sclerosis (135), 
graft-versus-host disease (136, 137), and osteogenesis imperfecta (138). For each clinical 
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application, adequate numbers of viable, transplantable donor cells need to be generated 
which retain their multipotency and are free of infectious agents. However, widely employed 
expansion protocols for hMSC still use animal serum in the culture medium (i.e. 10% FBS). 
FBS contains essential growth factors and nutrients needed for many cell cultures in vitro, 
however, the fact that it is of animal origin carries significant risks for the transmission of 
infectious agents and the potential for promoting or enhancing immune rejection. Therefore, 
the use of animal sera for cell-based therapies has come under scrutiny for the accreditation 
of clinical studies (139) and a number of alternative, human serum-based, media have been 
shown to be useful (140, 141). Since serum-free culture conditions may also be of great 
benefit, the growth promoting property of Panserin 401 (a commercially available medium, 
specifically developed for serum-free tissue cultures) on hMSC has been compared with that 
of the current standard medium (i.e. 10% FBS-containing medium).   
5.3 Materials and methods 
5.3.1 Cell culture 
Cancellous bone fragments were obtained from patients during routine surgical procedures 
(with informed consent according to local ethical board approval of the University Hospital, 
Aachen) and the MSC were selected by their adherence to tissue culture plastic (34). Briefly, 
the bone fragments were washed with DMEM (Cambrex, East Rutherford, USA) and the 
collected media was centrifuged at 500 g for 5 min. The resulting cell pellet was re-
suspended in 10 ml fresh DMEM supplemented with 10% fetal bovine serum (FBS; batch 
was selected by the capacity to support hMSC proliferation) (Biowest, Nuaille, France), 
transferred to a T75 flask (Greiner Bio-One, Frickenhausen, Germany) and maintained in a 
humidified cell culture incubator at 37°C and 5% CO2. In some experiments the isolation, 
adhesion and proliferation of hMSC were conducted solely in Panserin 401 (Pan Biotech 
GmbH, Aidenbach, Germany) supplemented with 2% FBS and growth factors (Panserin 
401/2% FBS+GF). Non-adherent cells were removed by medium exchange after one week. 
Subsequent medium exchange was performed every 3-4 days. When the cells reached near 
confluence, they were detached with trypsin/EDTA (PAA Laboratories GmbH, Pasching, 
Austria) and re-seeded at a density of 4000 cells/cm2. 
Multipotent differentiation capacity and surface marker profiles of the isolated hMSC were 
analyzed according to the guidelines set by the Mesenchymal and Tissue Stem Cell 
Committee of the International Society for Cellular Therapy (34) as demonstrated previously 
by our group (142). To analyse cell proliferation, hMSC from 4 human donors were seeded 
at 4000 cells/cm2 in 12-well plates in DMEM/10% FBS. The following day, the cells were 
washed with 0.1 M phosphate-buffered saline (PBS) and grown in DMEM- or Panserin 401-
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based media with or without FBS (2% or 10%) and growth factors (10 ng/ml epidermal 
growth factor (EGF), 1 ng/ml basic fibroblast growth factor (bFGF), 1 ng/ml platelet-derived 
growth factor BB (PDGF-BB) and 10 nM dexamathasone, all from Cell Concepts, Umkirch, 
Germany). For a detailed description of the various serum-free and serum-containing media, 
see Table 5.1. 
Table 5.1: Media composition. 
 
 
 
 
 
 
 
 
 
 
Panserin 401/2% FBS + GF 
Panserin 401 
2% FBS 
10 ng/ml EGF 
1 ng/ml bFGF 
1 ng/ml PDGF-BB 
10 nM Dexamethasone 
Panserin 401/2% FBS 
Panserin 401 
2% FBS 
Panserin 401/GF 
Panserin 401 
10 ng/ml EGF 
1 ng/ml bFGF 
1 ng/ml PDGF-BB 
10 nM Dexamethasone 
 
 
For adipogenic differentiation, hMSC were cultivated in DMEM containing 10% FCS, 0.5 µM 
dexamethasone, 0.5 µM indomethacin (Sigma, Steinheim, Germany), and 0.5 mM isobutyl-
methyl-xanthine (Sigma). Medium was changed every 3 days for 3 weeks. Oil Red O 
staining (Sigma) was used to visualize lipid droplets formation in differentiated adipocytes. 
Osteogenic differentiation was induced by cultivation of hMSC in DMEM containing 10% 
FCS, 20 nM sodium β-glycerophosphate (Sigma), 1 nM dexamethasone, and 50 µg/ml 1-
ascorbic acid 2-phosphate (Sigma). Medium was changed every 3 days for 3 weeks. 
Osteogenic differentiation was visualized by Alizarin-Red-S (Sigma) staining to demonstrate 
matrix mineralization associated with osteoblast differentiation. 
DMEM 
DMEM 
DMEM/2% FBS + GF 
DMEM 
2% FBS 
10 ng/ml EGF 
1 ng/ml bFGF 
1 ng/ml PDGF-BB 
10 nM Dexamethasone 
DMEM/10% FBS 
DMEM 
10% FBS 
Panserin 401 
Panserin 401 
Panserin 401/2% FBS + GF 
Panserin 401 
2% FBS 
10 ng/ml EGF 
1 ng/ml bFGF 
1 ng/ml PDGF-BB 
10 nM Dexamethasone 
Panserin 401/10% FBS 
Panserin 401 
10% FBS 
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5.3.2 Proliferation and cytotoxicity  
Cell proliferation and cytotoxicity were measured using the CellTiter-Blue Cell Viability Assay 
and CytoTox-ONE Homogeneous Membrane Integrity Assay (Promega, Madison, USA) 
according to the manufacturer’s protocol twice a week for three weeks without passaging 
cells. For cytotoxicity measurement, 100 µl of the supernatant were transferred into a black 
96-well plate, and incubated with 100 µl CytoTox-ONE for 10 min at 37°C. To measure 
proliferation, CellTiter-Blue was diluted 1:5 in medium and 1 ml added to each well for 1h at 
37°C and 5% CO2.  Subsequently, 200 µl of the supernatant were transferred into a black 96-
well plate. For both assays fluorescence intensity was measured using the fluorometer 
FLUOstar OPTIMA (BMG Labtech, Jena, Germany) with an excitation at 560 nm and 
emission at 590 nm. After washing with PBS, 1 ml fresh medium was added to the cells and 
incubated until the following measurement. 
5.3.3 Statistical analysis 
All data are presented as the mean value ± SEM. Statistical differences were determined by 
one-way ANOVA followed by Bonferroni post hoc testing. A p value of less than 0.05 was 
considered to be significant. All the statistical analyses and the evaluation of data were 
performed using GraphPad Prism version 4.03 (GraphPad Software, San Diego, USA). 
5.4 Results 
Although the present investigation was unable to demonstrate the usefulness of Panserin 
401 as a serum-free medium for the expansion of hMSC, its combination with 2% FBS and 
growth factors was found to be promote excellent hMSC proliferation. Cultivation of hMSC in 
non-supplemented DMEM resulted in the progressive detachment of the cells such that by 4 
days in vitro (DIV), no substrate-bound cells could be detected (Figure 5.1A). The lack of cell 
binding to the substrate meant that cell death could not be measured in these samples 
(Figure 5.1B). Although hMSC grown in Panserin 401 were able to maintain adherence to 
the tissue culture plastic, minimal proliferation was observed up to day 4, and cell numbers 
actually decreased thereafter, eventually reaching a steady-state at a lower cell number 
(Figure 5.1A). The level of cell death under these conditions remained low throughout the 
whole duration of the experiment (Figure 5.1B). Cell detachment, as demonstrated in 
DMEM-only medium, may have been due to the lack of binding proteins (e.g. fibronectin) 
normally found in serum. Interestingly, serum-free Panserin 401 was capable of supporting 
the maintained attachment of relatively small numbers of cells, although the accompanying 
data sheet confirmed the absence of any cell adhesive ECM proteins. However, it was clear 
that Panserin 401 alone was not suitable for promoting the rapid proliferation of hMSC. The 
successful expansion of hMSC with Panserin 401 required the additional use of low amounts 
EXPANSION OF HUMAN BONE MARROW-DERIVED MESENCHYMAL STROMAL CELLS: SERUM-
REDUCED MEDIUM IS BETTER THAN CONVENTIONAL MEDIUM 
 
31
 
of FBS (i.e. 2%) as well as growth factor supplements. The growth factors employed were 
PDGF, FGF2, EGF and the glucocorticoid dexamethasone, all of which have been shown to 
be potent mitogens for MSC (143-145).  
 
Figure 5.1: Human MSC demonstrate high proliferative capacity in Panserin 401 supplemented with 
2% FBS and growth factors. Proliferation (A) and cytotoxicity (B) of four different donors were monitored 
over a total culture time of three weeks in DMEM, Panserin 401, DMEM supplemented with 2% FBS and 
growth factors (GF), Panserin 401 supplemented with 2% FBS and growth factors, DMEM with 10% FBS or 
Panserin 401 with 10% FBS. Furthermore, the role of the individual supplements on hMSC proliferation (C) 
and cytotoxicity (D) were monitored using Panserin 401 supplemented with 2% FBS-only or with GF-only. 
Data are expressed as mean value ± SEM and compared with the standard medium DMEM with 10% FBS. * 
p<0.05; *** p<0.001. 
 
DMEM supplemented with 2% FBS and growth factors promoted a moderate increase in 
hMSC proliferation up to 10 DIV (reaching approximately 50 thousand cells per well), similar 
to that supported by DMEM/10% FBS (Figure 5.1A). Thereafter, cell numbers remained 
fairly constant in both media. Since elevated levels of cell death were detected between 13-
21 DIV in DMEM/10% FBS, the relative stability of cell numbers at these times must have 
been due to the balance between cell death and cell proliferation. Similarly, a balance 
between relatively limited cell death and cell proliferation must have been established by 
hMSC in DMEM/2% FBS+GF between 13-21 DIV. In contrast, hMSC grown in Panserin 
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401/2% FBS+GF demonstrated the greater enhancement of cell proliferation that was 
evident by 7 DIV, a rate that could only be matched by incubation of cells in Panserin 
401/10% FBS (Figure 5.1A). This rapid cell proliferation resulted in confluency 
(approximately 80 thousand cells per well) by 7 DIV with the densely packed hMSC 
appearing as swirls of similarly aligned, elongated cells and processes. Such densely 
packed swirls of confluent cells have been reported by others (28, 29). The Panserin 401/2% 
FBS+GF medium promoted only a minor increase of cell death that could be observed 
between 13-17 DIV.  
To elucidate which media supplement was essential for promoting hMSC proliferation, cell 
growth was monitored using Panserin 401 supplemented solely with 2% FBS (Panserin 
401/2% FBS) or solely with growth factors (Panserin 401/GF). HMSC cultivated in Panserin 
401 with only one supplement demonstrated no cell growth, both supplements (i.e. 2% FBS 
and GF) were required for the optimal proliferation (Figure 5.1C). Interestingly, seeded cells 
adhered well to the tissue culture plastic and revealed no cytotoxicity (Figure 5.1D).  
Isolation of hMSC from cancellous bone using the conventional medium DMEM/10% FBS 
revealed high numbers of adherent cells by one week after isolation (Figure 5.2A). However, 
isolation with Panserin 401/2% FBS+GF demonstrated even greater numbers of adherent 
cells by one week (e.g. Figure 5.2B). Low numbers of cells were isolated in Panserin 401 
supplemented with 2% FBS-only (Figure 5.2C), whereas no attached cells were observed 
using Panserin 401 with growth factors (Figure 5.2D). 
 
Figure 5.2: HMSC isolation applying different media. HMSC could be isolated from cancellous bone using 
DMEM/10% FBS (A), Panserin 401/2% FBS+GF (B), Panserin 401/2% FBS (C), but not using Panserin 
401/GF (D) (1 week after isolation). 
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Those cells that were isolated directly with Panserin 401/2% FBS+GF could be efficiently 
expanded over a number of passages with no detrimental effects on multipotency as 
demonstrated by differentiation into adipocytes (Figure 5.3A) and osteocytes (Figure 5.3B). 
 
 
Figure 5.3: HMSC isolated and expanded in Panserin 401/2% FBS+GF maintain multipotent capacity. 
(A) Adipogenic differentiation resulted in the formation of lipid vacuoles which were stained with Oil Red O 
whereas (B) osteogenic differentiation resulted in immense mineral deposition demonstrated by Alician Red 
staining. 
 
5.5 Discussion 
Comparing all data generated using the different media, it could be demonstrated that the 
medium providing optimal cell proliferation with only moderate cell death was Panserin 401 
supplemented with 2% FBS and growth factors. The employment of Panserin 401 medium 
for the expansion of hMSC enables the use of lower concentrations of animal serum, but this 
may still present a risk for infection or the development of host immune responses.  
In an earlier attempt to develop serum-free culture conditions for hMSC, the group of 
Meuleman and colleagues described the use of UltraCulture medium supplemented with 
serum substitute “UltrosaG” (146). Although this medium and supplement induced a greater 
rate of cell expansion than that supported by α-MEM/15% FBS and maintained multipotency, 
it was later discovered that UltrosaG contained low amounts of animal serum (139). The 
present data support the notion that supplementation of serum-free media with low amounts 
of FBS and growth factors is capable of promoting excellent hMSC proliferation.  
The present failure to demonstrate serum-free proliferation of hMSC suggests that 
alternative serum-free approaches using supplementation with bFGF, human albumin, 
hydrocortisone, selenite, insulin, transferrin and ethanolamine (141), should be considered 
for clinical expansion. However, although the above serum-free medium reported by Liu and 
colleagues promoted cell proliferation, it was unable to support the initial isolation of hMSC 
by adhesion (12). This suggests that undefined serum components were necessary for 
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colony formation. In a different approach, media supplemented with human platelet lysates 
(140, 141) proved to be excellent for hMSC isolation and cell proliferation. The 
aforementioned method still remains the most promising and safe method for large scale 
hMSC isolation and expansion without changing cell phenotype or loss of differentiation 
potential. 
5.6 Conclusion 
In summary, the present study demonstrated that Panserin 401, a medium specifically 
developed for serum-free cell cultivation, could not (acting alone) support hMSC expansion. 
However, supplementing Panserin 401 with 2% FBS and growth factors (PDGF, FGF2, EGF 
and dexamethasone) supported excellent isolation, proliferation and maintenance of 
multipotent differentiation capacity. 
GROWTH FACTOR AND CYTOKINE EXPRESSION OF HUMAN MESENCHYMAL STROMAL CELLS IS 
NOT ALTERED IN AN IN VITRO MODEL OF TISSUE DAMAGE 
 
35 
 
6. Growth factor and cytokine expression of human 
mesenchymal stromal cells is not altered in an in vitro 
model of tissue damage 
6.1 Abstract 
The beneficial effect of hMSC transplantation in a variety of cell-based intervention strategies 
is widely believed to be due to paracrine mechanisms. Here, the modification of hMSC 
cytokine and growth factor expression patterns have been studied following exposure to 
lipopolysaccharide (LPS) or to tissue homogenates (representing tissue debris) from normal 
and pathological tissues.   
Human bone marrow-derived MSC were stimulated with LPS or exposed to homogenate from 
normal or pathological rat spinal cord or heart. The expression profiles of a number of 
cytokines and growth factors were investigated using quantitative RT-PCR with human 
specific primers. The effects of tissue homogenates on hMSC proliferation and migratory 
behaviour were also investigated. 
Stimulation of hMSC with LPS resulted in an up-regulation of IL-1β, IL-6 and IL-8. However, 
the pattern of up-regulation varied between donor samples. Furthermore, LPS treatment 
resulted in a donor-dependent alteration of growth factor expression. Induction of a shift in 
expression pattern was not observed following exposure to homogenates from either normal 
or pathological tissues. Tissue homogenates did, however, stimulate cell proliferation but not 
migration. 
HMSC expression pattern is apparently stable, even when cells are confronted by debris from 
different tissue types. However, treatment of hMSC with LPS is able to change the expression 
of cytokines and growth factors in a donor-dependent manner which may enhance their 
potential use in regenerative medicine. 
6.2 Introduction 
Cell-based intervention strategies using hMSC are of great interest to basic scientists and 
clinicians. Assessment of the beneficial effects after transplantation of autologous or allogenic 
MSC has been performed in a variety of clinical trials including spinal cord injury (61, 62), 
acute myocardial infarction (134), multiple sclerosis (135), graft-versus-host disease (136, 
137), and osteogenesis imperfecta (138).  
In the case of transplanting MSC into spinal cord lesions, motor and sensory improvement in 
rodent models (49, 53, 57) as well as in phase I clinical trials (62, 123) have been reported. 
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Migration of transplanted cells to the site of injury was associated with a significant reduction 
of secondary tissue degeneration (57). Injection of MSC directly into the infarcted heart has 
also been reported to improve the left ventricular function in rats (147, 148), dogs (149), and 
pigs (150, 151). Even the first clinical trial in diseased heart demonstrated an significant 
improvement in global and regional left ventricular function after an intra-coronary infusion of 
MSC (134).  
The mechanism(s) responsible for such beneficial effects remain unclear. Four possible 
explanations have been proposed: (I) transplanted MSC differentiate into cells of the injured 
tissue (i.e. neurons and astrocytes in CNS, and cardiomyocytes in heart tissue) (37, 72, 79, 
80, 125, 152, 153); (II) grafted cells fuse with cells of tissue origin (19, 20, 154); (III) MSC 
modulate the recipients’ immune system (135, 155, 156); and (IV) donor cells release growth 
factors/cytokines which promote cell survival and proliferation of stem/progenitor cells residing 
in the damaged tissue as supporting the survival and regeneration of differentiated cells (127-
129, 131, 157). The hypothesis that MSC differentiate into either neurons/astrocytes or 
cardiomyocytes has aroused great interest but such suggestions must be balanced by the 
observation that such transdifferentiation appears to be a rare event (124, 149). It would also 
seem that cell fusion is a similarly rare event (19, 154). Since it was shown that these two 
possible mechanisms occur at only very low frequency, it is unlikely that they make a major 
contribution to functional improvement. Therefore, the secretion of growth factors/cytokines by 
MSC is widely believed to promote the beneficial effects. 
MSC are capable of expressing and releasing a variety of growth factors including VEGF, 
BDNF, NGF, bFGF and HGF (54). Neurotrophins such as BDNF and NGF increase the 
survival of injured CNS tissue in vitro and in vivo (158, 159). Similarly, a recent study has 
demonstrated cardioprotection by human MSC-derived conditioned medium in a porcine 
model myocardial infarction (160).  
The expression of different toll-like receptors (TLRs) on hMSC has also been demonstrated 
(161). These receptors are normally found on immune cells and are activated by molecular 
components found on microbes. However, endogenous non-pathogenic molecules (e.g. 
extracellular matrix, heat shock proteins or proteolytic cleavage products) have been 
demonstrated to activate TLR2 and TLR4 (162-165). The release of molecules and debris into 
the extracellular space is greatly increased in pathological tissues and might thus, be 
expected to trigger a shift in the pattern of hMSC growth factor or cytokine expression. The 
present investigation was undertaken to assess the hypothesis that such changes in growth 
factor/cytokine expression might be altered in response to exposure to debris in a tissue-
specific manner. 
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6.3 Material and methods 
6.3.1 Cell culture 
Cancellous bone fragments were obtained during operation procedures from fully anonymous 
patients (with informed consent according to local ethical board approval of the University 
Hospital, Aachen) and selected by their plastic adherence as demonstrated previously (see 
chapter 5.3.1) (166). Briefly, bone fragments were washed with Panserin 401 media (Pan 
Biotech GmbH, Aidenbach, Germany) and the collected media was centrifuged with 500 g for 
5 min. The cell pellet was resuspended in 10 ml fresh Panserin 401 media supplemented with 
2% fetal bovine serum (FBS) (Biowest, Nuaille, France) and growth factors (10 ng/ml 
epidermal growth factor (EGF), 1 ng/ml basic fibroblast growth factor (bFGF), 1 ng/ml platelet-
derived growth factor BB (PDGF-BB) and 10 nM Dexamathasone (all Cell Concepts, Umkirch, 
Germany), transferred to a T75 flask (Greiner Bio-One, Frickenhausen, Germany) and 
maintained in a humidified cell culture incubator at 37°C and 5% CO2. Non-adherent cells 
were removed by media exchange after one week. Medium exchange was performed every 3-
4 days. When the cells reached nearly confluence, the cells were detached with trypsin/EDTA 
(PAA Laboratories GmbH, Pasching, Austria) and re-seeded with a density of 4000 cells/cm2. 
For the following experiments cells in passage 5 were used. 
Multipotent differentiation capacity and surface marker profile of the isolated hMSC were 
analyzed according to the guidelines set by the Mesenchymal and Tissue Stem Cell 
Committee of the International Society for Cellular Therapy (34) as demonstrated previously 
(see chapter 5.3.2) (142, 166). 
6.3.2 TLR stimulation 
TLR stimulation was performed by exposure of hMSC to 10 ng/ml lipopolysaccharide (LPS; 
Sigma, Steinheim, Germany) in normal culture medium for 4 hours (161). 
6.3.3 Immunocytochemistry 
Fluorescence immunocytochemistry was performed on hMSC seeded in 12-well plates at a 
density of 4000 cells/cm2. After removal of the media and washing in PBS, cells were fixed 
with 4% paraformaldehyde in PBS for 30 min. Afterwards, the samples were washed three 
times with PBS and non-specific binding sites blocked by a 1 hour incubation in PBS 
containing 3% normal goat serum (Sigma), 1% bovine serum albumin (BSA, fraction 5, Serva, 
Heidelberg, Germany) and 1% Triton X-100 (Sigma). The primary antibody, anti-TLR4 (1:100, 
monoclonal, ab30667, Abcam, Cambridge, USA) was diluted in PBS containing 1% BSA and 
incubated at room temperature overnight. The secondary antibody goat-anti-mouse Alexa 594 
(1:500, Invitrogen) was also diluted in PBS containing 1% BSA and incubated for 2.5 hours at 
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room temperature. Finally, nuclei were stained with diamidinophenylindole (DAPI, 1:1000, 
Roche), cover-slipped with Fluoroprep (bioMerieux, Marcy l’Etoile, France) and observed 
using a Leica DM RX microscope (Leica, Wetzlar, Germany) with 20x objective. Omission of 
primary antibodies served as negative control and resulted in no detectable staining. 
6.3.4 Surgical procedure and tissue extraction 
All surgical procedures were performed with female Lewis rats (body weight approximately 
250 g) according to the guidelines of the regional ethical committee for North Rhine-Westfalia 
(AZ 50.203.2-Ac 23, 11/06 and 59.203.2-K 47, 43/03). Animals were housed under a 12:12 h 
dark light regime and allowed free access to water and standard laboratory chow. 
Spinal cord injury: Animals (n = 3) were anesthetized by inhalation of a mixture of isoflurane 
and air (induction: 4% isoflurane, maintenance: 1.8% isofluorane). The dorso-lateral surfaces 
of the spinal cord were exposed by laminectomy at level Th13 and a lateral funiculotomy of 
the left side of the cord was performed. Haemostasis was established and the muscle and 
skin closed in layers.   
Myocardial infarction: Induction of myocardial infarction was performed as described 
previously (167-169). Animals (n = 3) were anesthetized with an intraperitoneal injection of 
ketamine (50 mg/kg) and xylazine (10 mg/kg), intubated, and ventilated with room air. The 
chest was opened through the fourth intercostal space to expose the basal region of the heart. 
The left coronary artery was occluded by taking a stitch through the myocardium with a C-1 
taper needle, attached to 5-0 polypropylene suture, from the atrioventricular groove to the 
region of the pulmonary cone to encircle the artery and then tying a double knot in the suture. 
Harvesting of lesioned tissues: At 7 days post injury, animals were given terminal anaesthesia, 
the lesioned spinal cord or heart tissues were excised, frozen in liquid nitrogen and stored at -
80°C. For homogenization, 1 ml of Panserin 401 was added and tissue was homogenized in a 
Retsch MM300 Shaker (Retsch GmbH, Haan, Germany) three times for 2 min at 25 Hz. In an 
attempt to standardise the content of the different samples, the amount of protein per sample 
was measured using a BCA protein assay kit (Pierce, Rockford, USA) following the 
manufacturers instructions. The homogenates were stored at –80°C prior to use. 
Homogenates from three individual animals were mixed such that each culture was treated in 
a similar manner. For in vitro experiments of the effect of the homogenates on hMSC 
expression patterns, a final homogenate-derived protein concentration of 0.1 mg/ml in normal 
culture medium was used.  
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6.3.5 Proliferation assay 
Human MSC were plated in 12-well plates at a density of 4000 cells/cm2 in either control 
medium or medium supplemented with 0.1 mg/ml tissue extract. After 1 and 4 days in culture, 
cell proliferation was measured using CellTiter-Blue (Promega, Madison, USA) according to 
the manufacturer’s protocol.  
6.3.6 Cell migration assay 
For analysis of migration, a scratch assay was performed. A scratch with a 1 ml pipette tip was 
made through the diameter of confluent hMSC cultures in 12-well plates. To remove any non-
adherent cells, the cultures were washed twice with 0.1 M phosphate buffered saline (PBS) 
and photographed (0 h) using an inverse phase contrast light microscope (DM IL Invers, 
Leica, Wetzlar, Germany) and Diskus software (Diskus, Königswinter, Germany). Afterwards, 
1 ml of normal culture media (control), 100 ng/ml SDF1α (as positive control; Peprotech, 
Hamburg, Germany) (170), or homogenate was added to the cells and incubated at 37°C and 
5% CO2. After cultivation for 16 h and 24 h, samples were again photographed. For 
evaluation, the pixels of cell-free area were measured using ImageJ software 
(http://rsbweb.nih.gov/ij/). The area from 0 h was set as 100%.  
6.3.7 RNA isolation and gene expression analysis  
RNA was isolated using the RNeasy Micro Kit (Qiagen, Hilden, Germany) according to the 
manufacturer’s protocol. The RNA concentration of each sample was measured using a 
Nanodrop photometer (Nanodrop Technologies, Montchanin, USA). Reverse transcription was 
performed using the Taqman RT Kit (Applied Biosystems, Carlsbad, USA). 
Real-time PCR was carried out with an ABI Prism 7700 Sequence Detector using Taqman 
Universal PCR Master Mix (no UNG, Applied Biosystems) with the following pre-designed 
human-specific primer/probe sets (TaqMan Gene Expression Assays, inventoried, Applied 
Biosystems): BDNF (Hs00380947), bFGF (Hs00266645_m1), EGF (Hs00153181M1), GAPDH 
(Hs99999905_m1), HGF (Hs00300159_m1), interleukin (IL) 1β (Hs00174097_m1), IL-6 
(Hs00174131_m1), IL-8 (Hs00174103), NGF (Hs00171458_m1), neurotrophin (NT) 3 
(Hs00267375_s1), NT4 (Hs01921834_s1), stromal-derived factor 1α (SDF1α) 
(Hs00171022_m1) and VEGFα (Hs00904634_m1). For each amplification, the template was 
equivalent to 10 ng of total RNA. Measurements were performed in duplicate; a no-template 
blank served as negative control. All assays were performed using the manufacturer 
recommended universal cycling parameters (40 cycles of 94ºC for 20 s and 62ºC for 1 min). 
Amplification curves and gene expression were normalized to the house-keeping gene 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Gene expression was calculated 
using the ddCT method. 
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6.3.8 Statistical analysis 
Data are shown as average ± SD. Multiple group comparison was performed by one-way 
analysis of variance (ANOVA) followed by the Tukey post-hoc test (Prism4, GraphPad 
Software, Inc., San Diego, USA). Values of p<0.05 were considered as statistically significant.  
6.4 Results 
6.4.1 Characterization of hMSC 
Characterization of isolated hMSC was performed according to the Mesenchymal and Tissue 
Stem Cell Committee of the International Society of Cellular Therapy (34). As demonstrated 
previously in chapter 5, hMSC expressed CD73, CD90 and CD105, but were negative for 
CD11b, CD19, CD34, CD45 and HLA-DR. Multipotency was confirmed by differentiation into 
adipocytes, osteocytes and chondrocytes. 
Since the potential beneficial effects of hMSC transplantation (either spinal cord injury or the 
infracted heart) is thought to be due to the release of growth factors and cytokines, the basal 
expression of these factors by all three donors was investigated using quantitative RT-PCR 
(Figure 6.1). Donor heterogeneity could be observed in the basal expression of BDNF, HGF, 
NGF, SDF1α, IL-1β and IL-6, whereas the expression of bFGF, EGF, NT3, NT4, VEGFα and 
IL-8 was quite homogeneous.   
 
Figure 6.1: Basal expression of growth factors and cytokines is donor dependent. Quantitative RT-PCR 
was performed on three independent hMSC samples. Donor dependent-heterogeneity was detected in the 
basal expression of BDNF, HGF, NGF, SDF1α, IL-1β and IL-6, whereas the expression of bFGF, EGF, NT3, 
NT4, VEGFα and IL-8 appeared to be similar between donor samples. 
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6.4.2 LPS treatment of hMSC leads to an altered expression of cytokines and 
growth factors 
TLR4 expression by hMSC was confirmed by immunofluorescence (Figure 6.2A). Stimulation 
of TLR4 by exposure to LPS resulted in the up-regulation of cytokines IL-1β (133.74 ± 155.30-
fold) , IL-6 (24.11 ± 32.63-fold) and IL-8 (94.38 ± 60.21-fold) by hMSC obtained from three 
donors (Figure 6.2B) (161). However, the pattern of increased expression demonstrated 
apparent donor-dependent variability. Furthermore, LPS treatment revealed an altered growth 
factor expression as demonstrated by quantitative RT-PCR (Figure 6.2C). A down-regulation 
by cells from all three donors could be detected for the growth factors BDNF (0.09 ± 0.05-
fold), EGF (0.04 ± 0.02-fold), NT3 (0.07 ± 0.02-fold), NT4 (0.07 ± 0.02-fold) and VEGFα (0.26 
± 0.26-fold), whereas an up-regulation could be detected for bFGF (10.69 ± 16.05-fold). 
Interestingly, LPS stimulation resulted in an up-regulation in HGF (5.02 ± 7.49), NGF (3.26 ± 
2.41-fold) and SDF1α (9.93 ± 12.06-fold) expression by two of the investigated donors, 
whereas down-regulation of these factors could be observed for the third donor.  
 
Figure 6.2: LPS treatment of hMSC leads to an altered cytokine and growth factor expression.  TLR4 
expression by hMSC was demonstrated by immunofluorescence (scale bar 100 µm) (A). Quantitative RT-PCR 
revealed an enhanced expression of the cytokines IL-1β, IL-6 and IL-8 after LPS stimulation compared to 
control cultures (B). Altered growth factor expression after LPS treatment was demonstrated by quantitative RT-
PCR. BDNF, EGF, NT3, NT4 and VEGFα were down-regulated, whereas bFGF, HGF, NGF and SDF1α were 
up-regulated (C). 
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6.4.3 hMSC exposure to tissue homogenates does not alter cytokine or growth 
factor expression patterns 
To investigate if a shift in cytokine and growth factors expression patterns could also be 
induced by exposure to endogenous molecules liberated within debris, tissue homogenate 
from either normal or pathological rat spinal cord or heart was supplemented to the hMSC 
cultures. Quantitative RT-PCR using human-specific primers revealed no induction of the 
cytokine expression of IL-1β, IL-6 or IL-8, in contrast that the pattern of expression induced by 
exposure to LPS (Figure 6.3). 
 
Figure 6.3: Co-cultivation with tissue homogenate from normal or pathological tissue does not affect 
cytokine and growth factor expression. In contrary to LPS treated cultures, no induction in cytokine 
expression could be detected after treatment with tissue homogenate from either normal or pathological tissue. 
Furthermore, no altered growth factor expression was observed after co-cultivation. (n=3; *p<0.05). 
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Furthermore, the induction or reducing of the growth factor expression could not be detected 
after exposure to tissue homogenate from either normal or lesioned samples. 
6.4.4 Stimulation with tissue homogenate triggers hMSC proliferation but not 
migration 
To investigate whether the supplementation of tissue homogenate from either normal or 
pathological tissue has an effect on hMSC cultures, proliferative and migratory activity was 
investigated. As early as 1 day after exposure to tissue homogenate, an increase in cell 
numbers could be detected compared to control cultures (Figure 6.4A). After 4 days of 
exposure, the cell numbers of treated cultures were significantly increased. The effect of 
tissue homogenate on the migratory capacity was examined by scratch assays and revealed 
no effect on migratory behavior (Figure 6.4B). The migration of hMSC showed a trend for 
enhancement in response to SDF1α but this effect did not reach the level of statistical 
significance when compared to the control cells. 
 
Figure 6.4: Stimulation of hMSC with tissue homogenate induces proliferation but not migration. 
Induced cultures demonstrated significantly enhanced proliferation after 4 days of treatment (A). No effect after 
16h or 24h of stimulation could be observed in migratory activity as shown by scratch assays (B). (n=3; 
*p<0.05; **p<0.01). 
 
6.5 Discussion 
The present in vitro study was undertaken in an attempt to evaluate the possible 
mechanism(s) of action by which implanted hMSC exert the beneficial effects that have been 
reported in models of tissue pathology as well as in clinical trials. We tested the hypotheses 
that exposure of hMSC to homogenates (intended to represent tissue debris) from various 
tissues would cause a shift in cytokine and growth factor expression patterns, and that the 
expected shifts would be dependent on the type of tissue used to generate the homogenate. 
Although a shift of cytokine and growth factor expression could be clearly demonstrated after 
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exposure to LPS, no significant shift of expression patterns could be observed after exposure 
of cells to tissue homogenate (from any investigated source).  
The basal expression of the investigated molecules was donor dependent, supporting other 
reports (127, 161). Activation of TLR4 by LPS treatment led to an increase in the expression 
of the cytokines IL-1β, IL-6 and IL-8, by all donor samples, confirming the results of others 
(161). However, the present study demonstrated variability of the intensity of cytokine 
expression by the three different donors. An LPS-mediated shift of expression of growth 
factors bFGF, HGF and VEGFα has been previously reported (171, 172). However, these 
studies reported an increase in the expression of the above growth factors by all donors. The 
present investigation confirms the increased expression of bFGF (detected in all three 
donors), however, decreased VEGFα expression was demonstrated by all hMSC samples. 
Furthermore, LPS treatment in the current investigation led to an increase of HGF expression 
by two donors, whereas reduced expression was observed in the third donor sample. Such an 
apparent variability of donor cell responses to a single stimulus is a novel observation, as is 
the LPS-induced alterations of BDNF, EGF, NGF, NT3, NT4 and SDF1α expression.  
As mentioned above, the only growth factor that was up-regulated by all three donors after 
LPS treatment was bFGF. It has been reported that bFGF is involved in tissue remodelling 
and regeneration, has neurotrophic activity and seems to be a survival factor that blocks the 
apoptosis of neural cells (reviewed in (173)). Furthermore, bFGF is involved in cardiac 
protection (174) and initiates neovascularisation (neo-angiogenesis) in hypoxic or ischemic 
tissues (175).  
Interestingly, differences regarding the response to LPS stimulation could be observed for the 
growth factors HGF, NGF and SDF1α. The expression of these factors was increased in two 
donor samples, but was decreased in the third sample. HGF facilitates the growth, motility, 
and morphogenesis of various types of cells, i.e. vascular endothelial cells (176), neural cells 
(177, 178), hepatocytes (179) or hematopoietic cells (180). Moreover, HGF promotes repair, 
protection, and functional improvement of injured spinal cord (177) or heart (181). NGF is 
involved in the survival of CNS (reviewed in (182)) as well as cardiac tissue (183, 184) in vitro 
and in vivo. SDF1α acts as a potent cell attractant for lymphocytes (185) and has been 
reported to promote the survival of cardiomyocytes after myocardial infarction (186). 
Moreover, application of SDF1α leads to an outgrowth of postnatal dorsal root ganglions on 
inhibitory central myelin (187). Although it is well known, that the basal expression of different 
factors is donor dependent, an altered reaction to the same stimulus has not previously been 
reported. These observations confirm and extend the information regarding the apparent 
heterogeneity between MSC samples obtained from different donors (127, 142). Such 
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heterogeneity may have considerable consequences for the ability of certain populations of 
donor cells to deliver the anticipated beneficial effects. 
LPS treatment further led to a down-regulation of the growth factors BDNF, EGF, NT-3, NT-4, 
and VEGFα. BDNF facilitates almost all aspects of nervous system development and 
regeneration such as neuronal proliferation, neuronal migration, axon pathfinding, dendritic 
growth, and neuronal survival (188-190). Furthermore, BDNF is involved in vascularisation of 
the developing heart as well as promotes blood flow recovery and capillary density after 
cardiac injury (191, 192). EGF is involved in cell proliferation, differentiation, motility and blood 
vessel recruitment (reviewed in (193)). NT3 and NT4 belong to the family of neurotrophins 
which promote the survival and differentiation of existing and developing neurons (194). 
Application of NT3 after spinal cord injury supported re-growth of axons across the dorsal root 
entry zone and established functional connections with cells of the dorsal horn (195). NT3 has 
further been reported to be involved in the development of the heart (196) as well as impairs 
resting heart rates (197). VEGFα is involved in angiogenesis, functions as a chemoattractant 
for macrophages (198) and attenuates left ventricle fibrosis and cardiac dysfunction in 
ischemic heart (199) presumably by activating resting cardiac stem cells (200). Moreover, 
VEGFα has been reported to promote neural repair by gliogenesis, angiogenesis, and tissue 
sparing after contusion of rat the spinal cord (201, 202). Recently, Yao and colleagues (203) 
described, for the first time, the application of LPS-stimulated MSC in a disease model. 
Transplantation of LPS-stimulated MSC into the infarcted rat myocardium ameliorated cardiac 
function and reduced fibrosis to a more significant extent than non-treated MSC. Furthermore, 
such pre-conditioned MSC demonstrated greater engraftment and ensuing vascularisation. 
Since an increase of VEGF expression by LPS-stimulated MSC could be detected, the group 
assumed VEGF to be the factor responsible for the improvement. However, the current results 
indicate that LPS changes the expression of a number of factors, some of these changes 
being in a donor-dependent manner.  
Despite the apparent sensitivity (and variability) of donor hMSC responses to exposure to 
LPS, there were, surprisingly, no detectable changes in either cytokine or growth factor 
expression following exposure to tissue homogenate from either normal or pathological 
tissues. It could be argued that the choice of the concentration and storage of homogenate 
that was added to the culture medium (i.e. 0.1 mg/ml) was insufficient to be able to provoke a 
physiological response, but the observation of enhanced proliferation in all donor samples 
would argue against this possibility. Since the local ethics committee policy dictated that the 
age of donors as well as the anatomical origin of bone fragments used for hMSC isolation be 
kept fully anonymous, it cannot be excluded that the observed variability of expression 
patterns may have been due to differences in donor age or sample site. Furthermore, 
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although the novel (Panserin-based) medium with supplements was used to induce a more 
robust proliferation of donor hMSC, it cannot be excluded that that this choice of medium may 
have altered the sensitivity of the samples to the tissue homogenates as well as their ability to 
demonstrate changes of growth factor and cytokine expression (166).  
The composition of the Panserin-based medium used for hMSC isolation and expansion might 
also have influenced the results obtained from the migration assay. No differences in the 
migratory capacity of tissue homogenate stimulated cells could be observed when compared 
to the non-stimulated control cells. Indeed, the inclusion of a positive control for hMSC 
migration, SDF1α, induced a trend for increased migration when compared with the 
unstimulated control cells, but this did not reach statistical significance. Since the culture 
medium used was supplemented with bFGF, EGF, and PDGF-BB, all of which are known to 
enhance hMSC migration (204, 205), the further addition of SDF1α might have had little effect 
on an already stimulated population of cells. 
The present observations are in contrast to those of Chen and colleagues who reported an 
increase in growth factor (BDNF, NGF, VEGF and HGF) production of hMSC that had been 
exposed to conditioned medium derived from traumatic brain injury tissues (54). Although 
Chen and colleagues used ELISA for the demonstration of elevated levels of growth factors, 
there was no data presented about possible changes in the proliferation of the hMSC. Since 
the present study demonstrated homogenate-induced stimulation of cell proliferation, it is 
feasible that the increased levels of growth factors reported by Chen and colleagues may 
have been due to conditioned medium effects on cell numbers. Another possible reason for 
the apparent differences of hMSC to molecules/debris released by damaged brain and spinal 
cord may be related to the fact that these different regions of CNS undergo different 
responses to particular insults. For example, the exposure of brain and spinal cord to 
particular pro-inflammatory cytokines (e.g. recombinant TNFα or IL-1β) resulted in strikingly 
different tissue responses: blood brain barrier breakdown being more prominent in spinal cord 
than in brain tissue (206, 207). 
6.6 Conclusion 
These observations lead to the conclusion, that the pattern of cytokine and growth factor 
expression by hMSC is not altered when exposed to debris or molecules from normal or 
pathological spinal cord or heart tissue. The improvement in the regeneration of spinal cord 
injuries or myocardial infarctions after hMSC transplantation seems to be due to the donor-
dependent cytokine and growth factor expression pattern which, according to the present 
data, would not change when the cells encounter such tissues. However, pre-stimulation of 
cells with LPS results in a shifted pattern of cytokine and growth factor which may enhance 
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their potential use in regenerative medicine. Nonetheless, care must be exercised in the 
choice of candidate donor cells for pre-stimulation because considerable donor variability 
appears to remain a confounding issue. 
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7. Mesenchymal stromal cells immobilized in an oriented 3D 
scaffold transiently accelerate functional recovery after 
acute spinal cord injury 
7.1 Abstract  
HMSC have important features that make them of high interest in the repair of the injured 
spinal cord: (1) hMSC express and release a variety of growth factors important for supporting 
axonal outgrowth, (2) the morphology of the hMSC extracellular matrix they produce is 
capable of influencing the direction of axonal outgrowth. In an attempt to combine both 
important features, hMSC were seeded into 3D, type-I collagen scaffolds (that were 
engineered to present a highly oriented porous microstructure) and implanted into acute 
lateral resection injuries of the rat thoracic spinal cord to investigate aspects of graft-host 
integration and tissue repair. For this purpose, green fluorescent protein (GFP)-transduced 
hMSC were seeded onto the collagen scaffolds, and human fibroblast (hFbl)-seeded scaffolds 
and empty scaffolds served as controls. Motor and sensory function were investigated weekly 
for up to 8 weeks. Immunohistochemistry was then performed to evaluate axonal regeneration 
as well the astrocytic and inflammatory responses.   
Already 1 week after implantation, animals which received hMSC-seeded scaffolds 
demonstrated better functional improvement than the control animals, which was even 
significant after four weeks. This difference, however, was no longer significant at 8 weeks. 
Although only small numbers of hMSC could be identified within the scaffold at 8 weeks, 
transplantation of hMSC-seeded scaffolds had resulted in the regeneration of increased 
numbers of axons into the implant as well as decreased astroglial and inflammatory 
responses. The hMSC detected at 8 weeks were found to be chondroitin sulphate 
proteoglycan (CSPG)-positive and were located in a scaffold that contained elevated levels of 
CSPG. The combination of an oriented type-I collagen scaffold and hMSC thus resulted in the 
transient acceleration of functional recovery in the present model of acute spinal cord injury. 
This effect might be associated with their expression of CSPGs as well as the reported growth 
factor and cytokine release. 
7.2 Introduction 
Several different cell types are currently under investigation as therapeutic cell-based 
intervention strategies for spinal cord injury (SCI). Such cell types include Schwann cells (44, 
208), olfactory ensheathing cells (45), neural stem/progenitor cells from embryonic (46), foetal  
(47) or adult sources (209). Other encouraging cell-types include the MSC which can be 
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readily isolated from tissues such as bone marrow, expanded in vitro (28) and reintroduced 
into the patient as an autograft (62, 123).  
Transplantation of MSC in spinal cord lesions has been reported to result in motor and 
sensory improvements in rodent models of injury (49, 53, 57) as well as in phase I clinical 
trials (62, 123). Migration of transplanted cells to the site of injury was associated with a 
significant reduction of secondary tissue degeneration (57). Furthermore, donor MSC were 
observed to form longitudinally orientated guidance structures which supported axonal growth 
in vitro (210) as well as in vivo (49). The beneficial effects of MSC engraftment in SCI are 
likely to be due to the release of growth factors/cytokines which may promote cell survival and 
proliferation of host stem/progenitor cells residing in or near the damaged tissue, as well as 
supporting the survival and axonal regeneration of differentiated neurons (127, 129, 210, 211). 
Human MSC express a variety of cytokines such as IL-1β, IL-6 and IL-8 as well as growth 
factors including several neurotrophic factors such as BDNF, NGF, NT-3 and NT-4 (210, 211). 
Apart from the release of growth factors, the orientation of hMSC (and their extracellular 
matrix) is essential for the control of the direction of axon regeneration (210). It would be 
therapeutically advantageous to be able to control the orientation of donor hMSC and their 
ECM in relatively large lesions. Therefore, in the present thesis, hMSC were seeded into type-
I collagen scaffolds that presented an oriented microstructure (212) and were implanted into 
an rat model of acute spinal cord injury to investigate issues of graft-host integration the 
regeneration of damaged axons. 
7.3 Materials and methods 
7.3.1 Cell culture 
HMSC: The GFP-expressing hMSC were provided by Drs Seguera and Mallet (University of 
Paris, France) as part of the EU funded collaboration on stem-cell based intervention 
strategies for SCI (acronym: RESCUE). HMSC were cultivated in Panserin 401 medium 
supplemented with 2% fetal bovine serum (FBS) (Biowest, Nuaille, France) and growth factors 
(10 ng/ml epidermal growth factor (EGF), 1 ng/ml basic fibroblast growth factor (bFGF), 
1 ng/ml platelet-derived growth factor BB (PDGF-BB) and 10 nM Dexamathasone (all Cell 
Concepts, Umkirch, Germany)), transferred to a T75 flask (Greiner Bio-One, Frickenhausen, 
Germany) and maintained in a humidified cell culture incubator at 37°C and 5% CO2 (166) 
Adipogenic- and osteogenic differentiation capacity of the GFP-transduced hMSC were 
determined as described earlier in chapter 5.3.1 (142, 166).  
HFbl: A human foreskin fibroblast cell line (SM3) was used as a control cell-type. The cells 
were generated and provided by Drs. Devos and Klein (University of Montpellier, France) 
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following informed patient consent and approval of the local ethics committee. The cells were 
provided by colleagues as part of the EU-funded collaboration on stem-cell based intervention 
strategies for SCI (acronym: RESCUE). Fibroblasts were cultured on normal tissue culture 
plastic in DMEM/F12 (Lonza) containing 10% FBS and penicillin/streptomycin (PAA 
Laboratories GmbH). 
7.3.2 Scaffold seeding 
Three-dimensional scaffolds were provided by a local bioenterprise (Matricel GmbH, 
Herzogenrath, Germany) and cut into cylinders (2 mm diameter x 3 mm length) using sterile 
biospy punches (Kai Industries, Japan). Seeding was performed using a cell suspension with 
either 104 cells/µl (hMSC) or 2x104 cells/µl (hFbl). These different seeding densities were 
chosen due to size differences of both cell types. Furthermore, higher cell numbers of hMSC 
block the pores of the scaffold, leading to unequal distribution of the cells. For seeding, dry 
scaffold cylinders were dropped into the cell suspension and transferred into 12-well plates. 
To allow cell attachment, seeded scaffolds were incubated at 37°C for 3 h with a drop of 
media next to the scaffold to prevent dehydration. Afterwards cell-specific media were added. 
Some of the hMSC-seeded scaffolds were further processed for cell proliferation and 
distribution data after 1, 7 and 14 days in vitro. After fixation in 4% PFA, samples were 
embedded in a 5% gelatine (Merck, Darmstadt, Germany), 5% (w/v) sucrose (Merck) solution 
in 0.1M PBS and kept in a humidified chamber at 45°C overnight. Gelatine was allowed to 
polymerize the next day, at 4°C, for half an hour and was then frozen at -80°C in isopentane. 
20 µm thick longitudinal sections were cut using a cryostat and either processed for 
immunocytochemistry or proliferation analysis. Proliferation was evaluated by counting DAPI-
stained nuclei from 15 non-overlapping, randomly chosen, microscopic fields (100x 
magnification) from three scaffolds per time point.   
7.3.3 Behavioural analysis 
Female adult Lewis rats (Charles River, Sulzfeld, Germany) were maintained in accordance 
with the guidelines of the German animal protection statute and experimental protocols were 
approved by the regional ethical committee for North Rhine-Westphalia (AZ 50.203.2-Ac 23, 
11/06). A total of 29 female Lewis rats (Charles River, Sulzfeld, Germany) with a body weight 
of approximately 200 g were used. The animals were housed under temperature controlled 
conditions at 21 ± 1 °C, with a normal 12:12 h light/dark cycle. The animals were kept on a 
food-restriction protocol throughout the pre-operative training period and post-surgery. This 
food-restriction protocol involved a 12 g diet per day (which allowed the adult rats to maintain 
a stable body weight) with free access to water. The assessment of animal weight and 
behavioural analysis after surgery was performed on a weekly basis for up to 8 weeks. 
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7.3.3.1 CatWalk Gait Analysis 
Animals were trained daily on the CatWalk (Noldus Information Technology, Wageningen, The 
Netherlands) for 2-3 weeks prior to surgery. The use of the CatWalk for computer-assisted 
gait analysis and the required training protocol have already been described elsewhere (213-
215). Briefly, the CatWalk system consists of a glass runway (109 x 15 x 0.6 cm), located in a 
darkened room, which contains light from a white fluorescent tube. Internal reflection causes 
the light to be restricted to the glass surface plate under normal circumstances. Only at those 
points where an animal’s paw touches the surface of plate does light exit from glass floor. The 
scattered light demonstrates the contact area of the paw and is detected by a video camera 
(Sony 3CCD Color Video Camera; DXC-990/990P) positioned underneath the walk-way. The 
signal is digitized (50 half-frames/s) by an S-RGB frame grabber (Matrix Vision GmbH, 
Oppenheimer, Germany) and the acquired data compressed and stored for eventual analysis 
using the CatWalk software program (Hamers et al., 2001). Thus, a wide range of gait 
parameters can be measured from each run that a rat makes across the glass runway. The 
dietary food restriction of 12 g per day was used to motivate the animals, since each run was 
rewarded by access to a small number of foot pellets (Noyes Precision pellets PJPPP-0045; 
Sandown Chemical Ltd., Hempaton, UK) which were placed at the end of the runway. The 
training period ended after all animals were able to make at least three consecutive runs 
without interruptions. Importantly, the crossing time was controlled by only recording runs that 
required a duration of between 1 - 2 s. For correct locomotor analysis, the following walkway 
crossing criteria were used: (1) the rat needed to cross the walkway, without any interruption 
or problem, and (2) a minimum of three correct crossings per animal were required (but 8 
were recorded). For correct evaluation of the gait analysis, the three runs with crossing times 
closest to 1.4 seconds were chosen. In the present study, all individual crossings were 
analyzed for the duration of walkway crossing, the regularity index, base of support (hind-
limbs), intensity of paw placement, paw print area, paw max area, stance duration, swing 
duration, stride length and duty cycle (hind-limbs). 
7.3.3.2 Grid-walk 
The grid-walk provides a quantitative assessment of the animal’s ability to precisely control 
hind-paw placing while traversing a wire mesh walkway. The walkway consisted of wire mesh 
with regularly spaced diagonal bars (distance between bars is 3 cm). For correct analysis, the 
following criteria concerning grid-walk crossing were used: (1) the rat needed to cross the 
walkway, without any interruption or problem, and (2) a minimum of four correct crossings per 
animal were required. All runs were recorded using a video camera (Sony) to ensure correct 
analysis. Stepping errors consisting of misplacement of the hind-paw (such that it falls through 
the grid meshwork) were counted and the mean error rate from all four runs was calculated. 
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7.3.3.3 Von Frey sensory analysis 
Animals were placed in a plastic cage with a metal mesh floor, allowing them to move freely. 
They were acclimatised to this environment for approximately 10 min prior to testing, to allow 
for behavioural accommodation. A series of ten von Frey-type filaments with different stiffness 
(0.4, 0.6, 1, 1.4, 2, 4, 6, 10, 15, and 26 g; Stoelting, Wood Dale, USA) was employed to 
determine the 50% threshold for paw withdrawal to light mechanical stimulation, using a 
previously described “up-and-down paradigm” (216). Von Frey filaments were applied to the 
mid-plantar surface of each paw through the mesh floor. Probing was only performed when all 
paws of the animal were in contact with the floor. Each probe was applied to the foot until it 
just bent, and was kept in this position for 6–8 s. Interval between consecutive filaments was 
at least 5 s. The 50% paw withdrawal threshold was determined by initiation with the 2 g 
filament. In the absence of a paw withdrawal response, the next strongest stimulus in the 
filament series was presented. Once a paw withdrawal was observed, the next weakest 
stimulus in the filament series was chosen. After the first paw withdrawal, 5 further stimuli 
were presented until the series ended.  
Values obtained from animals one day prior to surgery were used for the demonstration of 
normal, baseline behaviour.  
7.3.4 Surgical procedure 
The day before surgery, animals were started on an immune suppression strategy to prevent 
rejection of donor human cells. For this purpose animals received 10 mg/kg cyclosporine 
(Novartis AG, Basel, Switzerland) and 4 mg/ml azathioprine sodium (GlaxoSmithKline, 
London, UK) intraperiteonal (i.p.).  
Under isoflurane inhalation anaesthesia, the back of the animal was shaved and the skin 
sterilized with 70% alcohol prior to incision along the midline, exposing the back musculature. 
Using blunt dissection, the superficial and deep muscle layers were cleared and retracted to 
expose the dorsal surface of the T9-T12 vertebrae. Fine bone rongeurs were used to perform 
a laminectomy of the T10-T11 vertebra, exposing the dorsal surface of the spinal cord. The 
dura was cut and reflected, after which a 2 mm long lateral funiculotomy was performed, 
followed by haemostasis using Spongostan. Subsequently, either a non-seeded scaffold, or a 
hFbl- or hMSC-seeded scaffold was implanted into the resection injury. 10/0 sutures were 
then used to secure the dural flap over the scaffold, thus helping to stabilize its position. The 
muscle layers were then closed using resorbable 6/0 suture. The skin was closed using 4/0 
sutures. After surgery, animals received immunosupression (i.p. 10 mg/kg cyclosporine, 4 
mg/kg azathioprine sodium and 2 mg/ml methylprednisolone (Sanofi-Aventis, Bridgewater, 
USA) according to the method of Pedersen and colleagues (217). Rats were also given 10 ml 
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of saline and antibiotics (0.01% baytril, Bayer, Leverkusen, Germany) subcutaneously, and 
were allowed to recover. The following day, the vast majority of the animals moved freely in 
their cage, and fed/drank without any indication of pain or discomfort. In those few cases of 
bladder dysfunction, which usually lasted for not more than 7 days, the bladders were 
manually voided on a daily basis. Immunosupression was performed until the end of the 
experiment using 10 mg/kg cyclosporine, 2 mg/kg azathioprine sodium and decreasing 
concentrations of methylprednisolone (1-7 days 2 mg/kg; 8-14 days 1 mg/kg; 15-end 0.5 
mg/kg) as recommended by Pedersen and colleagues (217).  
7.3.5 Tissue preparation 
Under terminal isoflurane inhalation anaesthesia, animals were perfused transcardially with 50 
ml PBS followed by approximately 300 ml of cooled 4% paraformaldehyde (PFA) in PBS. After 
perfusion, the spinal cord was carefully removed, post-fixed in 4% PFA for 24h and stored in 
20% sucrose for three days at 4°C. For histological processing, spinal cord segments 
including the lesion area were frozen in isopropanol (-80°C) and stored until required at –
80°C.  
7.3.6 Immunohistochemistry 
Adjacent serial longitudinal spinal cord sections (20 µm thick) were cut on a cryostat and 
collected onto adjacent SuperFrost Plus Gold glass slides (Menzel-Glaeser, Braunschweig, 
Germany), dried at 37°C for 4 h and stored at -80°C. For immunohistochemistry, the samples 
were washed three times with PBS and non-specific binding sites were blocked by a 1 h 
incubation in PBS containing 3% normal goat serum (Sigma), 1% bovine serum albumin 
(BSA; fraction 5, Serva, Heidelberg, Germany) and 1% Triton X-100 (Sigma). The primary 
antibodies were diluted in PBS with 1% BSA and 3% normal goat serum and incubated at 
room temperature overnight. The following monoclonal primary antibodies were used: anti-
chondroitin sulfate proteoglycans (CSPG, 1/200, Sigma), anti-GFP (1/200, Chemicon, 
Temecula, USA), anti-neurofilament 200 kDa (NF200, 1/2000, Sigma), and anti-human nuclei 
(hNuclei, 1/200, Millipore, Billerica, USA) as well as the following polyclonal antibodies: anti-
glial fibrilary acidic protein (GFAP, 1/2000, DAKO, Hamburg, Germany), anti-GFP (1/500, 
Chemicon), and anti-ionized calcium binding adaptor molecule 1 (Iba1, 1/1000, Wako, Neuss, 
Germany). Primary antibodies were detected by incubation of the appropriate combination of 
fluorochrome-conjugated secondary antibodies, i.e. either Alexa-Fluor 488 or 594 goat anti-
mouse IgG and Alexa-Fluor 488 or 594 goat anti-rabbit (1/500, Invitrogen, Carlsbad, USA) 
diluted in PBS with 1% BSA and 4,6-diamidino-2-phenylindole dihydrochlorid  (DAPI, 1/1000, 
Invitrogen) for 2.5 h at room temperature. Coverslips were then mounted onto the samples 
using Fluoroprep (BioMerieux, Nürtingen, Germany). Sections were visualized using an 
MESENCHYMAL STROMAL CELLS IMMOBILIZED IN AN ORIENTED 3D SCAFFOLD TRANSIENTLY 
ACCELERATE FUNCTIONAL RECOVERY AFTER ACUTE SPINAL CORD INJURY 
 
54 
 
inverted Zeiss Axioplan fluorescence microscope coupled to an on-line digital camera 
(Axiovision software).  
7.3.7 Evaluation of immunohistochemistry 
For quantification of the staining intensity, 8 sections (with an inter-section distance of 140 
µm) were analyzed per animal and marker. 
NF200: The whole transplantation area was photographed by employing the automatic image 
acquisition and mosaic reconstruction feature of the Zeiss AxioVision software using a 40x 
objective. The number of axons which crossed lines drawn across the images of the scaffold, 
100 µm from the rostral and caudal graft-host interfaces, as well as through the mid-portion of 
the scaffold, was counted (e.g. see Figure 7.1A). Any spinal nerve roots within the field  were 
excluded from the quantification. 
GFAP: To assess the astrocytic response at the implant-host interface, 3 pictures of the 
implantation site rostral, caudal and medial were taken using a 40x objective (Figure 7.1B). 
For quantification, images were all captured using the same exposure time and the mean grey 
value of each picture was evaluated using ImageJ software (http://rsbweb.nih.gov/ij/). The 
mean grey values of completely white and completely black images were used to set maximal 
and minimal values at 100% and 0%. 
Iba1: For the evaluation of the inflammatory response, 4 pictures of each section including the 
rostral, caudal, medial graft-host interfaces as well as from the central position within the 
scaffold were taken using a 40x objective (Figure 7.1C). Quantification was performed 
following same protocol as described for the GFAP staining (above). 
CSPG: To evaluate the level of extracellular matrix-related protein CSPG, within the scaffold, 
3 pictures of the implantation site including the rostral-, caudal- and medial graft-host 
interfaces were taken using a 40x objective (Figure 7.1D). Quantification was performed 
following same protocol as described for the GFAP staining (above). 
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Figure 7.1: Examples of the acquistion protocols for the quantification of immunohistochemical 
stainings. Regenerating axons (A) were stained for NF200 and all axons crossing the rostral and caudal lines 
within the scaffolds (arrows) as well as the middle line (dotted lines) were counted. For quantification of the 
astrocytic response (B), 3 pictures (squares) of the graft-host interface at rostral-, caudal- and medial positions 
of GFAP stained samples were taken and evaluated. The inflammatory response (C) was evaluated in Iba1-
stained sections by taking 4 pictures including the graft-host interface at rostral-, caudal- and medial positions 
as well as the central position (squares). Extracellular matrix deposition (D) was evaluated in CSPG-stainined 
sections from 3 pictures of the graft-host interface at the rostral-, caudal- and medial positions (squares). 
Addiontally, the CSPG staining of the scaffold center was evaluated. Scale bar: 200 µm. 
 
7.3.8 Statistical analysis 
Data are shown as average values ± SEM. Multiple group comparisons were performed by 
one-way analysis of variance (ANOVA) followed by the Bonferroni post-hoc test (Prism4, 
GraphPad Software, Inc., San Diego, USA). Values of p<0.05 were considered as statistically 
significant.  
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7.4 Results 
7.4.1 Characterization of hMSC 
After transduction of hMSC, all cells constitutively expressed GFP (Figure 7.2A). This had no 
apparent effect on hMSC multipotent characteristics as demonstrated by the differentiation 
into osteocytes (Figure 7.2B) and adipocytes (Figure 7.2C). 
 
Figure 7.2: Transduced hMSC remain their differentiation capacity. Transduced hMSC expressed 
constitutively GFP in culture (A) and remained their differentiation capacity into osteocytes (B) and adipocytes 
(C). Scale bar: 20 µm. 
 
7.4.2 In vitro cytocompatibility of the scaffold  
The 3D collagen scaffold used in this study presented continuous, longitudinally oriented 
guidance channels with numerous interconnected pores, as demonstrated by scanning 
electron microscopy (Figure 7.3A and B). Such oriented microstructure was intended to 
support the longitudinal orientation of the seeded cells as well the ensuing host axon 
regeneration. One day after seeding hMSC onto the biomaterial, the cells adhered and 
demonstrated an even distribution throughout the scaffold (Figure 7.3C-E). Interestingly, some 
of the hMSC expressed low levels of GFP, but these could still be clearly identified by anti-
GFP immunofluorescence (Figure 7.3F). Seeded scaffolds cultivated for up two 2 weeks in 
vitro revealed hMSC proliferation (Figure 7.3G), demonstrating the biocompatibility of the 
scaffold. 
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Figure 7.3: HMSC grow on oriented porous collagen scaffold. The scaffold consisted of oriented 
interconnected pores as demonstrated by electron microscopy (A+B). Seeded hMSC were evenly distributed 
throughout the scaffold (C-E) and could be stained for GFP (D). Interestingly, some cells expressed low visual 
levels of GFP, but could be identified by GFP staining (E+F). HMSC proliferated onto the collagen scaffold, 
demonstrating the biocompatibility of the material (G). Scale bar: 500 µm. 
 
7.4.3 Behavioural analysis after scaffold implantation 
All animals received a right-sided Th10-11 lateral funiculotomy and the lesion gap was directly 
replaced by either non-seeded (control) scaffolds (n=9) or hMSC-seeded scaffolds (n=10). 
Furthermore, hFbl-seeded scaffolds (n=10) were implanted as cellular controls. The 
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behavioural analysis was performed weekly after the surgery; however, to provide a better 
overview of the behavioural trends, data from 1, 4 and 8 weeks post surgery have been 
presented.  
7.4.3.1 Body weight  
Although all 29 animals showed a drop in body weight in the first week postoperatively, they 
all gained body weight in the weeks thereafter (Figure 7.4A). One week after surgery, 
significant (p<0.01) loss of weight compared to baseline level (BL: 201.6±1.25 g; indicated by 
dotted line) could be observed in animals receiving scaffold only (control: 185.3±2.82 g; hFbl: 
192.1±2.60 g; hMSC: 191.9±2.49). After 4 weeks, all animals recovered to BL level (control: 
197.6±2.19 g; hFbl: 206.0±2.69 g; hMSC: 206.5±2.29 g). At 8 weeks postoperatively, animals 
which received hMSC-seeded scaffold demonstrated significant (p<0.01) weight gain 
compared to BL values (control: 205.5±3.97 g; hFbl: 211.5±3.36 g; hMSC: 216.2±4.21 g). 
However, all three groups of animals did not display a significant difference in body weight at 
any time point in the study.   
7.4.3.2 Grid-walk 
In pre-operative BL measurements, all animals showed a mean stepping error rate of 
0.55±0.08 per run (as indicated by the dotted line) (Figure 7.4B). Evaluation of miss-steps 1 
week postoperatively could not be performed since the animals started to drag the hindlimbs 
after the first miss-step. Four weeks after surgery, all three groups demonstrated significantly 
(p<0.001) higher numbers of foot-falls compared to BL (control: 6.80±0.84; hFbl: 4.75±0.53; 
hMSC: 4.45±0.44). Furthermore, animals which received cell-loaded scaffolds presented 
significant (p<0.001) lower miss-steps than control animals. Eight weeks after surgery, the 
number of foot-falls by all three groups had decreased (control: 5.00±0.78; hFbl: 4.18±0.38; 
hMSC: 3.03±0.45), however these values were still significantly (control/hFbl: p<0.001; hMSC: 
p<0.05) higher than the baseline. The animals receiving hMSC-seeded scaffolds 
demonstrated still significant (p<0.001) lower error rates compared to animals of control and 
hFbl group. 
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Figure 7.4: Animals transplanted with hMSC show best weight recovery and significant increased 
coordination. Animals of all three groups demonstrated loss of weight 1 week after surgery (A). Control 
animals significantly lost weight compared to BL level (dotted line). Eight weeks after implantation, animals of 
the hMSC group significantly gained weight compared to BL. However, no significant weight differences could 
be observed between all three groups. Coordination was assessed by the number of miss-steps on a grid-walk 
(B).  Four and 8 weeks postoperatively, all groups presented significant higher numbers in miss-steps as 
compared to BL level (dotted line). Animals which received hMSC demonstrated significantly enhanced 
coordinative abilities at four and eight weeks after injury compared to control and hFbl groups. *p<0.05; 
**p<0.01; ***p<0.001. 
 
7.4.3.3 Von Frey filaments 
Using von Frey filaments enables the detection of sensory responses to a certain stimulus. 
Furthermore, detection of a sensory over-reaction, so-called allodynia, is possible. The pre-
operative 50% paw withdrawal threshold of the (ipsilateral) right hind-limb (RHL) was 
5.03±0.83 g (baseline and variation are indicated by dotted lines) (Figure 7.5A). The BL did 
not differ significantly from the thresholds after 1 week (control: 8.12±2.54 g; hFbl: 4.42±0.90 
g; hMSC: 7.437±1.54 g), 4 weeks (control: 6.36±2.07 g; hFbl: 4.75±1.45 g; hMSC: 6.32±2.77 
g) or 8 weeks (control: 5.33±1.95 g; hFbl: 7.02±1.54 g; hMSC: 4.14±0.91 g) of all three 
transplantation groups. The BL of the (contralateral) left hind-limb (LHL) was 4.88±1.06 g. No 
significant differences could be observed after 1 week (control: 3.82±0.94 g; hFbl: 4.21±1.11 
g; hMSC: 4.86±1.73 g), 4 weeks (control: 4.33±1.35 g; hFbl: 1.84±0.24 g; hMSC: 2.82±0.66 g) 
or 8 weeks (control: 2.71±0.44 g; hFbl: 3.47±0.91 g; hMSC: 4.19±1.32 g) after implantation of 
the (seeded) scaffolds (Figure 7.5B).  
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Figure 7.5: Sensory function is not impaired after scaffold implantation. Sensory function of both hind-
paws was assessed with von Frey filaments. The dashed lines indicate the BL ± variation before injury. No 
significant differences could be observed between the groups or to BL levels. 
 
Although the BL of all limbs was around 5 g, the high standard error in BL experiments as well 
as after surgery impeded conclusive evidence of enhanced/decreased paw sensitivity.    
7.4.3.4 CatWalk gait analysis 
For correct data analysis of the different gait parameters between all three groups, the 
crossing time is of great importance. Significant differences in the crossing time between the 
investigated groups could lead to false conclusions. Therefore, only 3 runs out of 8 recodings 
that were nearest to 1.4 s were used for evaluation. Pre-operative training on the CatWalk 
resulted in rapid runway crossings of 1.38±0.01 s (dotted line; Figure 7.6A). By 1 week after 
surgery, animals of all three groups were slower than in BL measurements (control: 1.48±0.03 
s; hFbl: 1.48±0.02 s; hMSC: 1.44±0.02 s). Furthermore, animals of the control group needed 
significantly (p<0.05) longer for each run compared to BL values. Four and 8 weeks 
postoperatively, the crossing time remained at BL levels (4 weeks: control: 1.38±0.02 s; hFbl: 
1.36±0.02 s; hMSC: 1.34±0.02 s; 8 weeks: control: 1.32±0.02 s; hFbl: 1.33±0.01 s; hMSC: 
1.35±0.02 s). Since there were no differences between the three groups, a legitimate 
comparison of data between all three groups can be made at all three time points.  
Regularity index. The regularity index defines coordination as the exclusive use of normal step 
sequence pattern during uninterrupted locomotion. Healthy animals have a regularity index of 
100% (dotted line; Figure 7.6B). One week after scaffold implantation, the regularity index of 
all three groups decreased significantly (control/hMSC: p<0.001; hFbl: p<0.01) compared to 
BL values (control: 91.54±2.47%; hFbl: 95.53±1.42%; 92.51±1.75%). Four weeks after 
surgery, the regularity index of all three groups nearly reached again 100% (control: 
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98.24±1.13%; hFbl: 99.80±0.20%; hMSC: 99.13±0.54%). Eight weeks after surgery, animals 
which received empty or hFbl-seeded scaffolds demonstrated a regularity index of 100%, 
whereas animals of the hMSC group had a lower regularity index of 97.93±0.78%.  
Stride length. The stride length gives the distance between the print of one hind-paw in one 
step cycle to the print of the same paw in the next step cycle. In uninjured animals the BL ratio 
of the ipsilateral to the contralateral side was 100% (dotted line; Figure 7.6C). The week after 
implantation of the scaffolds, the stride length was increased in all three groups (control: 
113.00±5.96%; hFbl: 103.90±4.81%; hMSC: 106.00±3.35%). The increase in stride length of 
the control animals was significant (p<0.001) compared to BL. Animals of all three groups 
presented almost normal stride length at 4 weeks (control: 103.90±3.84%; hFbl: 97.84±1.47%; 
hMSC: 96.92±3.46) and 8 weeks after surgery (control: 101.50±0.93%; hFbl: 97.43±1.31%; 
hMSC: 99.14±1.46%).  
Stance duration. The stance duration gives the time period in which one hind-paw is in contact 
with the CatWalk. In uninjured animals the ratio of the ipsilateral to the contralateral side was 
102±2.12% (dotted lines; Figure 7.6D). One week after surgery, the stance duration 
decreased in all three groups compared to BL (control: 64.56±6.10%; hFbl: 83.75±2.94%; 
hMSC: 92.05±3.38%). This decrease was significant (p<0.001) in animals of the control group. 
At 4 weeks after injury, the stance phase was still decreased (control: 65.72±5.27%; hFbl: 
80.93±4.35%; hMSC: 88.24±4.67%) whereas this decrease was significant to BL levels in 
animals receiving empty (p<0.001) or hFbl-seeded (p<0.01) scaffolds. Furthermore, the 
animals of the hMSC group demonstrated significantly (p<0.05) better recovery in stance 
duration compared to the control group. Eight weeks after injury all three groups presented 
recovery (but still lower than BL) in stance duration with no statistical differences (control: 
86.30±5.20%; hFbl: 87.98±2.96%; hMSC: 92.77±4.01%).  
Swing duration. The swing duration gives the time period in which one hind-paw has no 
contact to the CatWalk and therefore behaves complimentarily to the stance phase. The BL 
ratio of the ipsilateral to the contralateral side of all animals was 99.83±1.20% before surgery 
(dotted line; Figure 7.6E). Accordingly, the swing duration was increased 1 week after surgery 
compared to BL (control: 206.90±23.15%; hFbl: 159.70±21.69%; hMSC: 137.70±10.49%), 
whereas this increase was significant in animals receiving empty (p<0.001) or hFbl-seeded 
(p<0.001) scaffolds. Furthermore, animals of the hMSC group presented significantly 
(p<0.001) better recovery in swing duration compared to control animals. After 4 weeks, the 
swing duration of all three groups was still increased (control: 165.00±13.77%; hFbl: 
131.00±6.75%; hMSC: 112.40±5.76%). The difference of control animals to BL values as well 
as to animals of the hMSC group was still significant (p<0.001). Eight weeks after surgery, the 
swing duration of all three groups decreased towards BL levels (control: 134.50±7.19%; hFbl: 
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115.40±4.51%; hMSC: 110.70±4.52%). However, the swing duration of control animals was 
still significantly (p<0.05) higher compared to BL. 
 
Figure 7.6: Animals of the hMSC group showed a transient improvement in the recovery of gait 
parameters as assessed by CatWalk. No differences between all three groups could be observed in crossing-
time (x-time) (A), regularity index (B) and stride length (C). However, significantly improved function in stance 
duration (D), swing duration (E) and duty cycle (F) was observed in hMSC-transplanted animals at 1 and 4 
weeks with almost normal levels achieved by 8 weeks after injury. The dotted line indicates the values before 
injury. *p<0.05; **p<0.01; ***p<0.001. 
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Duty cycle. The duty cycle is a parameter that gives the stance duration as a percentage of 
the step cycle. Before injury the ratio of the ipsilateral to the contralateral side of the duty cycle 
was 100.10±0.84% (dotted line; Figure 7.6F). One week postoperatively, the duty cycle of all 
three groups decreased (control: 58.07±5.58%; hFbl: 84.72±3.10%; hMSC: 88.49±2.54%), 
however, this decrease was significant (p<0.001) only for the control group to BL values. 
Furthermore, the performance of control animals was significantly (p<0.001) lower than of 
animals which received hFbl- or hMSC-seeded scaffolds. At 4 weeks, the duty cycle of 
animals of the control and hFbl group was significantly (p<0.001) lower than the BL (control: 
63.58±4.92%; hFbl: 81.19±4.04%; hMSC: 88.45±4.68%). Animals of the hMSC group 
presented the same performance as after 1 week, but this was still significantly (p<0.001) 
better than of the control group. Eight weeks after injury, the duty cycle of all three groups 
maintained below BL (control: 80.89±3.95%; hFbl: 90.12±2.40%; hMSC: 94.83±2.08%). 
However, the control group was still significantly (p<0.001) lower than the BL. No statistical 
difference between all three groups could be identified. 
Base of support. The base of support (BOS) gives the average width between the hind-paws. 
Before injury the BOS of the hind-paws was 15.91±0.28 mm (dotted lines; Figure 7.7A). One 
week postoperatively, the BOS of the control and hFbl group was lower, the BOS of the hMSC 
group higher than BL (control: 14.90±1.47 mm; hFbl: 15.04±0.91 mm; hMSC 17.84±0.85 mm). 
At 4 weeks after injury, the BOS of animals which received hFbl-seeded scaffolds was at BL 
level, whereas the BOS of control animals and animals which received hMSC was increased 
(control: 18.54±0.89 mm; hFbl: 16.30±0.99 mm; hMSC: 18.99±1.04 mm). After 8 weeks, the 
BOS of all three groups was higher than BL values (control: 18.04±0.87 mm; hFbl: 18.02±0.92 
mm; hMSC: 18.67±0.83 mm). However, no statistically differences between all three groups or 
to BL values could be detected for any time point. 
Print area. The print area gives the average area of the footprint during contact to the 
CatWalk. The ratio of the print area of the ipsilateral to the contralateral side was 
104.10±2.97% in uninjured animals (dotted lines; Figure 7.7B). One week postoperatively, 
animals of all three groups presented a significant (p<0.001) decrease in print area compared 
to BL values (control: 34.31±5.85%; hFbl: 49.38±2.33%; 67.06±4.32%). Although there was 
no statistical difference detectable between all three groups, animals with cell-seeded 
scaffolds performed better than animals of the control group. Furthermore, better performance 
was presented by animals which received hMSC than those with hFbl. After 4 weeks, the print 
area of all three groups increased, but was still significantly (control/hFbl: p<0.001; hMSC: 
p<0.01) lower than the BL (control: 42.54±5.59%; hFbl: 64.61±5.82%; hMSC: 77.40±5.28%). 
However, the print area of the hMSC group was significantly (p<0.05) higher than that of the 
control group. At 8 weeks, the print area maintained below BL values (control: 70.72±6.66%; 
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hFbl: 77.47±6.66%; hMSC 82.87±4.87%) and was even significantly lower than BL in animals 
of the control (p<0.001) and hFbl (p<0.01) group. Although animals that received hMSC-
seeded scaffolds still presented the best recovery in print area at eight weeks, the 
improvement was no longer significant. 
Maximum area. The maximum area (max area) indicates the size of the footprint at the 
maximum contact to the CatWalk. The max area is given as the ratio of the ipsilateral to the 
contrlateral hind-paw. Before surgery, the BL of the max area was 105.50±3.42% (dotted 
lines; Figure 7.7C). The data for the max area was very similar to that already described for 
the print area. The week after surgery, the max area decreased significantly (control/hFbl: 
p<0.001; hMSC: p<0.05) in all three groups (control: 36.11±5.78%; hFbl: 56.24±2.67%; 
hMSC: 74.27±5.05%). After 4 weeks, the max area of all three groups was slightly increased, 
but still significantly (p<0.001) below BL in animals of the control and hFbl group (control: 
43.96±5.63%; hFbl: 71.20±6.59%; hMSC: 83.32±5.84%). The improvement in max area was, 
however, significantly (p<0.01) increased in animals which received hMSC-seeded scaffolds 
compared to control animals. Eight weeks after implantation, the max area of all three groups 
maintained below BL values (control: 73.19±6.30%; hFbl: 83.83±6.98%; hMSC: 89.63±4.89%) 
and for animals of the control group, this difference was still significant (p<0.01). Although 
animals which received hMSC-seeded scaffolds still presented the best recovery in max area 
after 8 weeks, the improvement was no longer significant. 
Intensity. The intensity is defined as the average intensity of max area. The more pressure the 
animals paw exerts, the larger is the total area of skin-floor contact and the brighter the pixel. 
The BL ratio of the ipsilateral to contralateral side of the intensity was 104.20±2.30% (dotted 
lines; Figure 7.7D). One week after implantation, the intensity of all three groups was below 
BL level (control: 60.11±7.10%; hFbl: 82.44±4.63%; hMSC: 91.20±4.36%), whereas the 
intensity of the control animals was significantly (p<0.001) decreased. This gait parameter 
demonstrated the most striking effect of implanting hMSC-seeded scaffolds with almost BL 
values already after one week. At 4 weeks, the intensity of animals of the control and hFbl 
group was significantly (p<0.001) lower than BL values, whereas animals of the hMSC group 
remained at BL level (control: 56.55±4.29%; hFbl: 74.46±5.14%; 98.13±5.96%). Additonally, 
the intensity of animals receiving the hMSC was significantly (p<0.001) improved compared to 
control animals. By 8 weeks, however, this difference decreased, but was still detectable. 
Furthermore, animals of the control and hFbl group presented some recovery in intensity, 
whereas the control group remained significantly below BL values (control: 77.52±5.35%; 
hFbl: 82.79±4.66%; hMSC: 94.92±5.17%). 
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Figure 7.7: HMSC-transplanted animals showed a transient improvement in the recovery of gait 
parameters as assessed by the CatWalk. No significant differences between all three groups could be 
observed in base of support (BOS) of the hind-paws (A). However, improved function in print area (B), max 
area (C) and intensity (D) was recorded in hMSC-transplanted animals as early as 1 week after injury. 
Furthermore, animals of the hMSC group presented significant recovery in these gait parametes compared to 
control animals at 4 weeks after injury. This difference, however, was reduced at 8 weeks. *p<0.05; **p<0.01; 
***p<0.001. 
 
7.4.4 Histological analysis of transplant-host interactions  
7.4.4.1 Survival of transplanted cells 
Transplanted cells within the scaffolds were identified by immunohistochemical staining of 
hMSC with anti-GFP antibody (Arrows; Figure 7.8A-D) and of hFbl with anti-human nuclei 
antibody (Figure 7.8E+F). Staining for GFP was essential due to low levels of GFP expression 
determined in the in vitro experiments, prior to implantation. Interestingly, hMSC demonstrated 
a substantially better survival than hFbl. In particular, hMSC could be identified in 60% (6 out 
of 10) whereas hFbl could be detected in only 10% (1 out of 10) of the animals in each group 
(Figure 7.8G). Furthermore, transplanted hMSC could only be identified near the center of the 
scaffold (Figure 7.8A+B) with no evidence of migrated cells into the host tissue. However, 
some autofluorescence could be detected within the host’s tissue in some cases (asterisk; 
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Figure 7.8A). In the one case where hFbl could be identified at eight weeks after implantation, 
these cells were also found within the scaffold with no sign of migration into the host’s tissue 
(Figure 7.8E+F). However, due to the staining of the human nuclei, only a high magnification 
image can be presented. Interestingly, although only few transplanted cells could be identified, 
the transplanted scaffolds were heavily infiltrated with cells (Figure 7.8C-F).     
 
Figure 7.8: Transplanted hMSC can be identified eight weeks after implantation. Immunofluorescence 
stainings of longitudinal spinal cord sections were prepared to identify transplanted cells. Only a few donor 
hMSC (arrows) could be identified within the collagen scaffold (dotted line) and there was no migration into 
surrounding host tissue (A+B). However, some autofluorescence within the host tissue could be identified in 
some cases (asterisk in A). Higher magnification of identified hMSC revealed high infiltration of host’s cells into 
the scaffold (C+D). Few transplanted hFbl could only be identified in one animal at eight weeks after 
implantation (E+F). Quantification revealed better survival of hMSC than hFbl up to 8 weeks after surgery (G). 
Scale bar: 200 µm (A+B); 50 µm (C+D); 20 µm (E+F). 
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7.4.4.2 Host axonal regeneration 
The re-growth of axons into the site of the injury is an important parameter to evaluate axonal 
regeneration. Regenerating axons were visualized using NF200 staining and could be 
identified in all three animal groups (Figure 7.9A-C). However, quantification revealed 
significantly higher numbers of regenerating neurons in hMSC-seeded scaffolds compared to 
non-seeded controls (control: 9.77±1.07; hMSC: 15.43±0.92; p<0.01). Numbers of axons 
within the hFbl group were 11.31±1.08 compared to 9.77±1.07 in the control group (not 
significant; figure 7.9G). For the quantification process only axons within the scaffold were 
counted and any present spinal nerve roots were excluded (asterisk; Figure 7.9C+D). 
Interestingly, the regenerating axons formed bundles and grew along the pores of the scaffold 
which was fully covered by infiltrated cells (Figure 7.9D-F).    
7.4.4.3 Host astrocytic response 
The astrocytic response after injury to the spinal cord leads to the formation of a glial scar 
which separates the damaged tissues from the intact tissue. The glial scar is characterized by 
elevated GFAP expression and could be detected at the host-scaffold interface in all three 
transplantation groups (Figure 7.10A-C). Furthermore, occassional GFAP-positive astrocytes 
were found to have migrated up to 200 µm along the pores of cell-seeded scaffolds (Figure 
7.10B-F). Quantification of the astrocytic response revealed a significantly (p<0.001) lower 
expression of GFAP in animals which received cell-seeded transplants compared to the 
control, non-seeded group (control: 1.11±0.03%; hFbl: 0.88±0.02%; hMSC 0.85±0.02%) 
(Figure 7.10G). 
7.4.4.4 Inflammatory response 
To evaluate the inflammatory response provoked by the transplantation of the cell-seeded and 
non-seeded scaffolds, staining of Iba1, a marker for microglia and macrophages was 
performed. The expression of Iba1 could be identified in all three groups around the lesion as 
well as throughout the scaffold (Figure 7.11A-C). Although many macrophages/microglia 
infiltrated the scaffold, DAPI counterstaining indicated that there were still numerous cells of 
unknown phenotype that had infiltrated into the scaffolds in high numbers (Figure 7.11D-F). 
Quantification of the inflammatory response revealed a significant (p<0.001) decrease of Iba1 
expression in animals that received the cell-seeded implants compared to control, non-seeded 
implants (control: 1.34±0.01%; hFbl: 1.21±0.01%; hMSC: 0.87±0.00%). Furthermore, hMSC-
seeded implants provoked a significantly lower inflammatory response than was induced by 
hFbl-seeded scaffolds (p<0.001; Figure 7.11G). 
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Figure 7.9: Immunohistochemitstry of longitudinal sections of the implants for NF200 to demonstrate 
that axonal regeneration is greater in animals which received hMSC-seeded scaffolds. Axonal outgrowth 
into the scaffold (highlighted by dotted line) could be detected by NF200 staining in all three groups at 8 weeks 
after implantation (A-C). DAPI staining revealed that regenerating axons grew along the pores of the scaffold 
which had been infiltrated with cells of unknown phenotype as seen by the overview picture (D) and in higher 
magnification from D (E-F). Quantification of the axonal ingrowth (without any spinal nerve roots marked by an 
asterisk in C) revealed significant higher numbers of regenerating neurons in hMSC-transplanted animals 
compared to non-seeded controls, with intermediate values being observed in hFbl-seeded scaffolds (G). Scale 
bar: 200 µm (A-D); 50 µm (E+F). **p<0.01. 
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Figure 7.10: Immunohistochemistry for GFAP demonstrates that cell-seeded implants induce a reduced 
host astrocytic response after implantation. Astrocytic response to the scaffold (dotted line) could be 
detected with GFAP staining in all three groups (A-C). Occassional astrocytic profiles were found to migrate up 
to 200 µm into cell-seeded scaffolds (B-D). High magnification image of the host-scaffold interface from D 
(square) demonstrates the alignment of ingrowing astrocytes (E+F). Quantification of the astrocytic response 
revealed that both groups which received cell-seeded scaffolds (i.e. hFbl or hMSC) demonstrated significant 
lower GFAP staining at the graft-host interface than was seen in the group receiving the non-seeded scaffold. 
Scale bar: 200 µm (A-D); 50 µm (E, E’). ***p<0.001. 
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Figure 7.11: Immunohistochemistry for Iba1 demonstrated that hMSC-seeded scaffolds induce the 
lowest extent of host inflammation. Macrophages and microglia could be identified by Iba1 staining 
throughout the scaffold and the surrounding host tissue in all three groups (A-C). Although macrophages and 
microglia could be detected within the scaffold, the majority of cells within the scaffold’s pores remained 
unidentified (D; high er magnification: E+F). Quantification the inflammatory response revealed significantly 
decreased staining in cell-seeded implants (i.e. hFbl and hMSC) compared to empty scaffolds. Furthermore, 
hMSC-seeded scaffolds demonstrated significantly lower inflammatory responses than were seen in response 
to the hFbl-seeded scaffolds. Scale bar: 200 µm (A-D); 50 µm (E+F). ***p<0.001. 
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7.4.4.5 Extracellular matrix production 
The highly sulphated extracellular matrix-related protein, CSPG, is a major constituent of the 
glial scar and its expression is markedly elevated following tissue injury (218, 219). CSPG 
expression could be detected around the lesion in all three implantation groups (Figure 7.12A-
C). However, a markedly intense CSPG staining could be identified in the center of hMSC-
seeded implants (Figure 7.12C). Although only few donor hMSC survived until the end of the 
experiment, the remaining, viable cells were found to be responsible for the intense CSPG 
expression (Figure 7.12D-F). Moreover, the expression and secretion of CSPG by hMSC was 
further confirmed subsequent in in vitro investigations (Figure 7.12G-I). Quantification of the 
CSPG staining demonstrated a significantly (p<0.05) lower expression around hFbl-seeded 
scaffolds compared to control- and hMSC-seeded scaffold implants (control: 0.65±0.01%; 
hFbl: 0.59±0.01%; hMSC: 0.66±0.02%) (Figure 7.12J). However, quantification of the CSPG 
staining within the center of hMSC-seeded implants was significantly (p<0.001) higher than in 
non- and hFbl-seeded implants (control: 0.38±0.01%; hFbl: 0.41±0.01%; hMSC: 1.53±0.06%) 
(Figure 7.12K). 
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Figure 7.12: CSPG immunoghistochemistry demonstrates the expression of this important ECM-related 
molecule by hMSC in vivo and in vitro. The extracellular matrix protein CSPG was expressed around the 
implant in all three groups (A-C). Interestingly, CSPG could additionally be identified within the scaffold of 
hMSC-seeded implants (C). Double immunofluorescence demonstrated that hMSC expressed CSPG in vivo 
(D-F) and in vitro (G-I). Quantification revealed significantly decreased CSPG staining only around hFbl-seeded 
implants (J). However, quantification of the CSPG staining revealed significantly increased expression in the 
center of hMSC-seeded scaffolds compared to non- and hFbl-seeded scaffolds (K). Scale bar: 200 µm (A-C); 
20 µm (D-I). *p<0.05; ***p<0.001. 
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7.4.4.6 Correlation of behavioural performance and axonal regeneration 
To evaluate if the number of NF200-positive axons detected by immunohistochemistry may 
have an impact on the behavioural performance in grid-walk experiments at 8 weeks after 
surgery, these parameters from each individual animal were correlated.  
As observed in the behavioural analysis, animals of the hMSC group presented a significantly 
lower numbers of foot-falls in grid-walk experiments compared to animals of the control and 
hFbl groups (see figure 7.4B). Furthermore, immunohistochemistry revealed higher numbers 
of axons in the hMSC-seeded scaffolds (see figure 7.9G). However, no significant correleation 
could be observed between these two paramaters (R²=0.03; Figure 7.13).  
 
 
Figure 7.13: Correlation of behavioural analysis with axonal regeneration into the scaffolds. For 
correlation analysis, the following parameters were evaluated for each animal at 8 weeks after scaffold 
implantation: number of miss-steps in grid-walk experiments and the number of NF200-positive axons found in 
the scaffolds. Although animals with higher numbers of NF200-positive axons had fewer miss-steps, the 
correlation between these 2 parameters was weak.   
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7.5 Discussion 
Implantation of immobilized MSC has the great advantage that the cells should stay at the 
area of interest rather than migrating to other areas. A number of different biomaterials have 
been investigated for the delivery of MSC into spinal cord lesions, such as hydrogels (220) or 
denuded human amniotic membrane (221). However, these biomaterials have no intrinsic 
guiding or orientational structures that could enable a directed axonal regeneration through 
the lesion site.  
After implantation of the oriented biomaterial, animals of all three groups presented a minor 
weight loss at 1 week. This expected surgery-induced weight loss was compensated at 4 
weeks and further increased at 8 weeks.  
The present use of an oriented biomaterial for such a strategy (i.e. a collagen scaffold seeded 
with hMSC) has demonstrated a transient acceleration of functional recovery in an acute 
model of spinal cord injury. Furthermore, the porous microstructure of the scaffold persisted in 
all three groups during the whole experimental procedure and could, in theory, facilitate further 
axonal regeneration beyond 8 weeks. Implantation of hMSC, however, demonstrated to have 
an early effect directly after surgery, suggesting that hMSC influence the host tissue by tissue 
sparing. Due to the high heterogeneity between different hMSC samples (211), this effect 
might be donor-dependent. Since only cells of one donor were used in this study, further 
investigations need to correlate the ECM, growth factor and cytokine composition of different 
donor samples with the behavioural results to identify hMSC with the highest improving 
properties.  
The use of the CatWalk gait analysis system enabled an objective and reliable method of 
evaluating locomotor parameters after lateral funiculotomy and the direct implantation of 
oriented scaffolds. Although all animals were trained to run continuously onto the CatWalk and 
only 3 runs out of 8 were evaluated that were nearest to 1.4 s, animals of all three groups 
presented longer runtimes 1 week postoperatively. Four and 8 weeks after surgery, the 
crossing time of all animals decreased and was even a little bit lower than before surgery. 
Since there were no significant differences in body weight and crossing time between all three 
groups, the results of the CatWalk gait analysis system can be objectively valuated. The 
regularity index, a measure for the exclusive use of normal step sequence pattern, was 
significantly reduced at 1 week compared to BL values, but was almost normalized in all three 
groups after 4 and 8 weeks. At 8 weeks, however, one animal of the hMSC group still 
presented some irregularities. 
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As early as 1 week after implantation, functional parameters like stance and swing duration, 
duty cycle, print and max area, as well as intensity of paw placement all showed a significant 
but transient increase in the rate of improvement (at 4 weeks post implantation) in animals 
which received hMSC-seeded scaffold compared to control animals. However, 8 weeks after 
implantation, the statistical significance of this effect was no longer detectable, but the positive 
trend was nonetheless clear. Furthermore, front-limb/hind-limb coordination was additionally 
significantly improved after 4 and 8 weeks in the hMSC-seeded scaffold group compared to 
control animals, as demonstrated by grid-walk experiments. Interestingly, this functional 
improvement was detectable in all animals despite the fact that only low numbers of donor 
cells could be detected within the scaffold in 60% of the animals. Although, the number of 
detectable donor cells was low, there was no evidence of cell migration into the host tissue. 
This suggests that there was a relatively poor survival rate of donor cells which may have 
been caused by the immediate transplantation of cells and scaffold into the lesion site. It has 
already been demonstrated in a contusion injury model that rat MSC show a significantly 
better survival rate when transplanted 1 week after injury, when compared with cells that were 
implanted directly after injury (49). Interestingly, the survival of hFbl, which served as a cellular 
control, was even lower: only 10% of the animals revealed viable donor hFbl. The better 
survival of hMSC might be due to their reported immunosuppressive properties (222-225). 
Others have suggested that these  immunosuppressive properties might also be responsible 
for the reduced astrocyte and macrophage/microglia reactivity (226). 
The sensory function of both hind-paws was not consistently changed during the whole 
experimental procedure as demonstrated by von Frey filaments. This is likely due to the fact 
that the ascending sensory fibers located in the dorsal funiculus, were not affected by the 
lateral funiculotomy.  
Significantly higher numbers of NF200-positive axons could be identified in animals which 
received hMSC-seeded scaffolds compared to control animals, even though only few donor 
hMSC could be detected within the scaffolds at 8 weeks after transplantation. The 
regenerating axons formed bundles in a direction that followed the pores of the scaffold. 
Interestingly, these pores were filled by host cells of unknown phenotype. These cells, 
presumably Schwann cells or fibroblasts, must have invaded the scaffold after implantation. 
Schwann cells could be easily be identified by staining for the low affinity nerve growth factor 
receptor p75. Identification of fibroblasts is, however, more complicated due to the lack of cell-
specific markers. One possibility to identify fibroblasts would be the staining for fibronectin 
(227). Unfortunately, hMSC and other cell types express fibronectin as well (228) and double-
immunofluorescence staining might not satisfactorily clarify the phenotype of these cells.  Due 
to the limited amount of spinal cord sections and the difficulties to perform double-
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immunofluorescence staining, these investigations could not be performed in this study, but 
should be included in further investigations.  
Elevated GFAP staining surrounding the implant could be identified in all three groups. 
However, implantation of either hMSC- or hFb-seeded scaffolds resulted in a significantly 
decreased astrocytic response. The decreased astrogliosis in animals which received cell-
seeded implant might have contributed to the increased ingrowth of regenerating axons.  
CSPG, a major component of the glial scar, is widely believed to limit axonal growth after 
spinal cord injury (218, 219). Staining of CSPG could be identified around the implanted 
scaffold in all three groups. Decreased CSPG expression surrounding the implant could only 
be detected in animals which received hFbl-seeded implants. Interestingly, animals receiving 
hMSC-seeded scaffolds demonstrated significantly higher CSPG expression within the 
scaffold compared to non- and hFbl-seeded scaffolds. Double-immunofluorescence 
demonstrated that hMSC express CSPG in vitro and in vivo. Therefore, it is likely that the 
strong CSPG expression found within the scaffold of hMSC-seeded implants was a residue of 
early proteoglycan expression from donor hMSC, which were subsequently lost. Although 
CSPG expression in spinal cord lesions is regarded to have a negative impact on regenerative 
capacity (229-231), a recent report by Rolls et al. suggests that beneficial effects of CSPGs on 
axonal regeneration are also possible (232). This beneficial effect of CSPG has been reported 
to be due to the modulation of macrophage and microglia behaviour, therefore affecting the 
overall repair process. Furthermore, regulation of other aspects of macrophage/microglia 
phenotype by CSPGs, i.e. phagocytosis or neurotrophic factor secretion has also been 
suggested. Expression of CSPG directly after injury promotes spinal cord repair and 
decreases tissue loss at the injury site. These observations lead to the conclusion that the 
acute implantation of highly CSPG-expressing hMSC into the lesion site may have promoted 
some degree of spinal cord repair. This might further explain the prominent behavioural effects 
observed 1 week after the implantation of hMSC-seeded scaffolds. In the present investigation 
no double-immunofluorescence staining of CSPG and NF200 could be performed due to the 
GFP expression by transplanted hMSC and the limited amount of sections. Further 
investigations should include such double-staining to correlate the regrowing axons with the 
CSPG expression within the scaffold. 
Since CSPG expression is thought to modulate macrophage and microglia function, the 
distribution and intensity of Iba1 staining in the present investigation is of particular interest. 
Iba1 expression was present in all three implantation groups and could be found in the host 
tissue as well as in the scaffold. However, decreased levels of Iba1 staining were detected in 
the hMSC group, suggesting lower macrophages/microglia infiltration than in the control- and 
hFbl groups. This observation tends to support the observations of Roll et al. (18) and might 
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contribute to an understanding of the apparent (but transient) beneficial effects brought about 
by hMSC-seeded scaffold implantation.   
Macrophages and microglia induce a reactive process of secondary tissue degeneration and 
cell death in the area surrounding the original injury by their expression and release of 
metalloproteinases, proteolytic- and oxidative enzymes (233, 234). The extent of such 
secondary tissue degeneration around the implant has been investigated with NeuN staining, 
as demonstrated recently by Davies et al. (235). It would be interesting to know if implantation 
of hMSC- seeded scaffolds would be able to preserve more neurons around the lesion than 
control scaffolds. The observed behavioural improvement already 1 week after injury suggests 
that the beneficial effect by hMSC-seeded implants is the result of spared tissue rather than 
regrowing axons. Therefore, future investigations should include NeuN-staining of these 
implants already after 1 week after injury.  
However, macrophages have also been reported to promote beneficial effects after spinal 
cord injury through the phagocytosis of myelin debris, which is known to inhibit axonal 
regeneration (236, 237). However, the inflammatory response in the spinal cord proceeds at a 
slower rate than in other tissues, leading to only a slow removal of tissue and myelin debris 
(238). The influence of the inflammatory response after spinal cord injury is clearly a complex 
and somewhat controversially discussed area of research, however a consequence of 
inflammation would be to induce the production of neurotrophic factors like NGF, FGF, and 
GDNF (239, 240).    
7.6 Conclusion 
It is clear that the regeneration process of the injured spinal cord is a very complex issue in 
which numerous factors play crucial roles, including ECM-, growth factor- and cytokine release 
by resident and implanted cells. Their impact on tissue sparing, axon regeneration and 
myelination are issues that can profoundly affect functional outcome after injury and 
implantation. The present study has demonstrated some interesting but transient beneficial 
effects of acutely transplanted hMSC-seeded scaffolds into experimental spinal cord lesions.  
However, there are clearly many more questions that need to be answered before any firm 
conclusion can be drawn about the potential usefulness of such an intervention strategy in 
promoting tissue repair or axon regeneration after spinal cord injury. 
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8. General discussion 
The aim of this thesis was to broaden the knowledge about the fate and function of MSC in 
their use in transplantation strategies for spinal cord injury. Four different explanations for their 
beneficial effects in SCI had already been suggested:  
(1) MSC transdifferentiate into cells of the neural lineage and replace lost cells (72-80) 
(2) Grafted MSC fuse with cells of the host’s nervous system to impart their beneficial 
effects (19) 
(3) Grafted MSC modulate the host’s immune system (156) 
(4) Grafted MSC produce a number of different growth factors that promote neuronal 
survival and axonal growth  (54, 127, 129, 131). 
In vitro transdifferentiation using chemical agents or growth factors has aroused great 
scepticism since this effect occurred within a time scale of minutes to hours after induction, a 
speed that was not comparable with the pace of the normal developmental process (114). The 
neuronal-like morphological changes induced by such stimulation were interpreted as being 
due to environmental stress, leading to physical contraction of the cells without an increased 
expression of neuronal markers (241). To further support this notion, several other stressors, 
such as detergents, chloride and extreme pH were also found to induce similar morphological 
changes. Time-lapse video-microscopy revealed that cellular shrinkage was responsible for 
the appearance of the neurite-like processes (241). This mechanism was further determined 
to be due to the breakdown of the actin cytoskeleton (115).   
The fusion of MSC with cells of host’s nervous system and the subsequent apparent adoption 
phenotype of the recipient cells was suggested to improve functional recovery after SCI. 
However, the frequency of spontaneous fusion is very low and therefore can not explain spinal 
cord regeneration (19). 
Modulation of the host’s immune system by transplanted MSC certainly could explain the 
functional recovery after SCI.  Indeed, MSC have the capacity to inhibit the cell division of 
immune-competent cells, resulting in a lower inflammatory response (242). 
The last issue of the expression of growth factors could also contribute to tissue sparing and 
axon regeneration. Several growth factors are reported to be expressed by MSC, i.e. BDNF, 
bFGF, NGF and VEGF (54, 131). However, this growth factor expression exhibits donor 
variability which influences the extend of neuritic outgrowth (127). 
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In the following section, the main results in this thesis will be summarized and discussed. 
Furthermore, the implications of the present results for future research will be considered. 
8.1 HMSC express neural-related markers 
In the last ten years, several in vitro and in vivo investigations have been performed which 
claimed to demonstrate the ability of MSC to differentiate into cells of the neural lineage (49, 
65, 72-80). These studies aroused great interest since such a capacity would open extensive 
possibilities for autologous therapeutic treatments in a variety of neurological disorders. 
However, many of these studies suffered from the methodological weakness of evaluating 
expression patterns for neural-related markers only after induction or implantation (37, 72, 
113).  
In this thesis, the expression of several neural-related markers could be demonstrated in 
undifferentiated hMSC by PCR and immunocytochemistry. The hMSC expressed neural-
related markers such as nestin, Enolase2, Nurr1 and MAP1b. More interestingly, however, 
was the identification of the immense donor-dependent heterogeneity between the samples. 
For example, DRD2, NFL, MBP and STX1A could only be identified in some of the donor 
samples, although all cells had been isolated from the patient bone marrow and expanded 
using the same culture medium and protocol. This inter-donor variability in neural-related 
marker expression is of immense importance when attempting to understand the apparent 
controversy regarding the ability of such cells to transdifferentiate.  
This on-going discussion has been stimulated by recent reports of hMSC transdifferentiation. 
It has been claimed that hMSC isolated from placenta (243) or umbilical cord (244) are 
capable of such transdifferentiation. Macias and colleagues described an elevated expression 
of β-III tubulin and NF200 after induction of placenta-derived hMSC using a differentiation 
medium containing dimethylsulfoxide (DMSO) (243). Although all 3 donor hMSC samples 
demonstrated a dramatic change in cell morphology and marker expression, it is most likely 
that the DMSO-containing induction protocol resulted in cellular shrinkage and breakdown of 
the actin cytoskeleton, as demonstrated previously with bone marrow-derived hMSC (115, 
241). Furthermore, the data of the present thesis has demonstrated that there are immense 
differences in marker gene expression between donors. Therefore, the evaluation of only two 
markers without corresponding functional investigations is insufficient to support claims of 
efficient transdifferentiation. The report by Zhang and colleagues has suggested 
transdifferentiation of hMSC derived from umbilical cord to a neural stem cell phenotype after 
cultivation in serum-free medium supplemented with bFGF, EGF and B27 (244). Formation of 
spheres and expression of nestin was regarded as functional conversion to neural stem cells. 
However, nestin expression prior to transdifferentiation had not been evaluated. As clearly 
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demonstrated in the present thesis, nestin expression may be detected in 100% of the bone 
marrow-derived hMSC and, thus, cannot be regarded as incontrovertible evidence of 
transdifferentiation.  
Although there is a substantial number of publications claiming to present protocols capable of 
supporting transdifferentiation (e.g. application of chemical compounts (37, 68-71), growth 
factors (72-75) or neurosphere-like cultivation (76-81)), by hMSC derived from different 
sources, the heterogeneity between different donor hMSC samples suggests that true 
transdifferentiation of hMSC is an unlikely event, or at best, still remains to be clearly defined.      
8.2 Serum-reduced expansion of hMSC 
For the translation of MSC-based transplantation strategies from the laboratory bench to the 
clinic, the use of a standardized serum-free medium is essential. The conventional medium 
used for laboratory expansion of MSC contains 10% serum. Such animal- or donor-derived 
sera might transfer infectious agents or lead to an elevated immune response (139). 
Therefore, it was deemed timely to assess the potential of the newly developed and 
commercially available serum-free medium, Panserin 401, on the isolation and expansion of 
hMSC.   
Isolation and proliferation of hMSC were investigated in Panserin 401 media without serum, 
supplemented with 10% FBS or with 2% FBS and growth factors, and compared with the 
conventional medium of DMEM with 10% FBS. Although Panserin 401 was designed for 
serum-free expansion of a number of different cell types, hMSC could not be isolated and 
expanded without serum. However, the combination of Panserin with reduced serum (2% 
FBS) and growth factors was able to support significantly greater hMSC proliferation than was 
seen with conventional medium. Furthermore, Panserin 401 supplemented with 2% FBS and 
growth factors did not change hMSC multipotency as demonstrated by adipogenic and 
osteogenic differentiation. Thus, the identification of a serum-free cultivation protocol for the 
clinical application of hMSC was not achieved in this thesis. However, a substantial reduction 
of serum levels was accomplished which, furthermore, presented improved cell proliferation. 
Due to this lower serum concentration, the possibility of using the patients own serum for 
hMSC isolation and expansion could be considered.  
However, the development of functional serum-free culture conditions for the expansion of 
bone marrow-derived hMSC has recently been reported by two individual groups (245, 246). 
Mimura and colleagues applied a medium that was initially developed for embryonic stem cell 
cultivation (247), which was further supplemented with bFGF, heparin, and TGF-β1. The 
cultivated hMSC cell line (UE7T-13) maintained the expression of CD73, CD90 and CD105, 
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as well as adipogenic and osteogenic differentiation capacity. Since these results were 
obtained with a single hMSC cell line, the capacity of efficient isolation and expansion of 
hMSC by this serum-free medium needs to be further investigated. Chase and colleagues 
employed a commercially available medium (StemPro MSC SFM by Invitrogen) supplemented 
with PDGF-BB, bFGF and TGF-β1 (246). This serum-free medium revealed the same 
proliferation rate and differentiation capacity as with the conventional medium (DMEM 
supplemented with 10% FBS). However, even though these initial experiments were 
performed using a pool of four different donors, it cannot be excluded that the cells from the 
individual donors grew with different proliferation rates. Clearer data would have been 
generated if the investigators had decided to analyze the responses of the individual donors 
separately. The comparison of isolation efficiency and the generation of sufficient cell numbers 
between the serum-free and conventional medium was, however, not presented. 
Although a growth factor composition, including bFGF and PDGF-BB, was applied in the 
present thesis, serum-free cultivation of hMSC could not be achieved. The novel and 
promising results presented by the Mimura and Chase research groups suggest that further 
investigations into serum-free cultivation using Panserin 401 should also include the 
supplementation of TGF-β1.      
8.3 Growth factor and cytokine expression by hMSC 
Increasing evidence has indicated that the beneficial effects of donor MSC in tissue defects 
might be due to the expression of growth factors and cytokines (248). Although the expression 
of some of these molecules has already been presented (54, 127, 131), the question as to 
whether the expression of molecules might be differentially regulated by the local 
environments of specific damaged host tissues had not been addressed.  
In this thesis, it could be demonstrated that the basal expression of the investigated growth 
factors and cytokines was donor-dependent. Interestingly, the regulation of growth factor and 
cytokine expression by LPS was additionally found to be donor-dependent. Since it was of 
interest to determine whether hMSC change their growth factor and cytokine expression 
patterns when implanted into lesioned spinal cord, an in vitro assay with tissue extract from 
normal and injured rat spinal cord was performed. To further evaluate the tissue-specificity of 
the expression pattern change, the effects of tissue extracts from normal and injured rat heart 
were also investigated. Although the growth factor and cytokine expression pattern could be 
altered by LPS stimulation, cultivation with tissue extract did not influence this pattern. 
However, it could be demonstrated that tissue extract enhanced hMSC proliferation but had 
no effect on cell migration. 
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These results indicate that hMSC maintain their expression patterns when implanted into 
spinal cord lesions. In contrast to the observations of this thesis, a recent report by Nicaise et 
al. describes the existence of growth factor expression changes of rat MSC after incubation 
with brain or spinal cord extract from amyotophic lateral sclerosis affected rats (249). The 
stimulation with the extracts resulted in a significant increase in NGF, BDNF and VEGF 
expression, whereas bFGF, IGF1, GDNF and HGF remained unaffected. A change in the 
growth factor expression of rat MSC upon stimulation with rat tissue extract is possible, but if 
these results can be transferred to human MSC remains unknown.  
By further investigating the effect of heart tissue, it could be similarly demonstrated that there 
was no tissue-specificity in the growth factor and cytokine expression pattern. Therefore, the 
immense differences in basal expression patterns between different donors could influence 
the anticipated beneficial effect after hMSC transplantation in spinal cord lesions. It has to be 
suggested that some donor cells may not improve functional recovery after SCI due to their 
inappropriate expression pattern. However, LPS-treatment was demonstrated to alter the 
growth factor and cytokine expression which may, in theory, enhance the beneficial properties 
of hMSC when used in regenerative medicine. 
In the report of Neuhuber and colleagues, it could be demonstrated that the variability in 
growth factor and cytokine expression by different hMSC samples had an immense impact on 
the functional and histological outcome after implantation into rat spinal cord lesions (127). To 
further support their results, dorsal root ganglia were incubated with conditioned media from 
different donors. Interestingly, although all conditioned media supported axonal outgrowth 
compared to normal culture medium, no correlation between the in vitro and in vivo results 
could be observed (127).  
These results suggest that such in vitro data may not be representative of the underlying 
mechanism of functional improvement that have been observed in vivo.   
8.4 Accelerated but transient spinal cord recovery induced by implantation of  
a microstructured 3D scaffold seeded with hMSC 
The regenerative properties of MSC in spinal cord injury have mainly been investigated using 
compression models of SCI followed by the injection of MSC directly into the lesion site (49, 
50, 56) or the surrounding tissue (57, 250). However, sufficient bridging of the lesion may 
require the immobilization of MSC within a biomaterial. Therefore, the goal of this thesis was 
to investigate the potential beneficial effects of combining hMSC and a microstructured 3D 
scaffold for experimental spinal cord repair. The oriented pores of the microstructured scaffold 
were intended to guide regrowing axons through the lesion site.   
GENERAL DISCUSSION 
 
83 
 
Earlier investigations of spinal cord regeneration by MSC have used the BBB score (251) to 
rate the functional outcome (49, 50, 53, 56, 127, 221). This score, however, was developed 
for contusion injuries of the spinal cord and the (subjective) correct rating is impeded by fast 
moving animals. In this thesis, the gait analysis was performed using the CatWalk gait 
analysis sytem which enables reliable objective quantitative data on numerous gait 
parameters after different spinal cord injury models (213, 214). Furthermore, this was the first 
application of the CatWalk gait analysis system to investigate the effect of MSC 
transplantation in acute spinal cord lesions.     
The implanted hMSC-seeded scaffolds demonstrated an early increase in recovery of motor 
function by 1 week after implantation, which was statistically significant by 4 weeks. However, 
little further improvement could be detected by the end of the experiment. It therefore has to 
be concluded that hMSC have an important function in the early recovery after SCI. On the 
other hand, Hofstetter and colleagues compared direct and delayed (7 days post injury) 
transplantation of rat MSC into a T9 contusion injury and reported functional improvement only 
after delayed application (49). However, others have reported that delayed (9 days) 
transplantation of rat MSC in a T9 clip compression model resulted in no functional 
improvement (56). Therefore, it might be possible that the application of MSC preparations 
from different species in a number of spinal cord injury models may have led to the apparent 
variability in their effects on functional outcome. 
Immunohistochemistry revealed that, by 8 weeks post implantation, only small numbers of 
hMSC could be identified in 60% of the animals. However, significantly more regenerating 
axons could be detected in animals which had received hMSC-seeded scaffolds. Furthermore, 
the glial and inflammatory responses were reduced in the scaffold+hMSC group. HMSC-
seeded scaffolds were found to be filled with CSPG and double immunofluorescence revealed 
that remaining hMSC were CSPG-positive. Since in vitro investigations have revealed that the 
extracellular matrix of hMSC is capable of directing (to some extent) the axonal outgrowth 
from dissociated adult rat dorsal root ganglia (252), it may be concluded that CSPG, shown in 
the present thesis to be expressed by these cells, may have contributed to this effect.   
The reduction in the astrocytic and inflammatory responses might be related to the immuno-
modulatory properties of hMSC (226). CSPG expression has widely been regarded to impair 
axon regeneration in the lesioned spinal cord. However, a beneficial effect of elevated CSPG 
expression has also been reported (232). This effect is considered to be due to the modulation 
of macrophage/microglia function and an early increase of expression has been reported to 
promote spinal cord repair. By implanting CSPG-expressing hMSC directly into the lesion, 
such modulation might have taken place, resulting in the early effect observed by the 
behavioural analysis. However, since the present investigation only included 
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immunohistochemical analyses at the later, 8 week, survival time, such a suggestion must 
remain pure speculation. Nonetheless, the early (though transient) improvement of function 
suggests that the likely mechanism of action of donor hMSC is by modulation of the local 
environment (e.g. tissue sparing) within the injured spinal cord by the release of growth 
factors, cytokines and ECM molecules. Such tissue sparing has been previously reported 
following the implantatiojn of MSC from a range of different species into a number of different 
spinal cord injury lesion models (53, 56, 57, 127).  
8.5 Future perspectives 
In this thesis it became evident that each donor hMSC preparation had its own individual 
growth factor and cytokine expression pattern and that not all samples are likely to be suitable 
for cell implantation strategies for spinal cord repair. Therefore, it is of great importance to 
determine which expression pattern for these molecules is most likely to promote spinal cord 
repair. Such information will be crucial for the transfer of such a therapeutic approach to a 
clinical application.  
The combination of hMSC and an oriented 3D scaffold was also demonstrated to have 
important properties in the transient acceleration of spinal cord repair following acute lesions. 
The present thesis suggests that such improved function is likely to be due to the production 
of growth factors, cytokines and ECM which modulate the environment rather than 
transdifferentiating into cells of the neural lineage.  
The transfer to clinical application of an autologous combinatory intervention strategy is, so 
far, limited. If it is known which donor hMSC have the best regenerative properties, an 
autologous approach may still be impracticable, since isolation and characterization of the 
cells is too time-consuming to provide the early effects of hMSC transplantation. However, the 
use of well characterized allogenic hMSC for transplantation might be practicable. Since 
hMSC have hypoimmunogenic properties (253), transplantation can also be performed with 
mismatched individuals. Furthermore, transplanted hMSC do not replace cells of the 
destroyed tissue but modulate the initially injured microenvironment. Long survival of the 
transplanted hMSC in the spinal cord seems to be not essential.   
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10. Abbreviations 
3D      three dimensional 
ASCL1   achaete-scute complex homolog 1 
AT cells      autoimmune T cells 
BDNF     brain-derived neurotrophic factor 
bFGF     basic fibroblast growth factor 
BL     baseline 
BOS     base of support 
BSA     bovine serum albumin 
CNS     central nervous system 
CNTF     ciliary neurotrophic factor 
CSPG     chondroitin sulfate proteoglycans 
DAPI     4,6-diamidino-2-phenylindole dihydrochlorid 
DMEM    Dulbecco’s Modified Eagle Medium 
DMSO    dimethylsulfoxide 
DRD2     dopamine receptor D2 
EDTA     ethylene diamine tetra acedic acid 
EGF     epidermal growth factor 
ESC     embryonic stem cell 
FACS     fluorescent activated cell sorting 
FBS     foetal bovine serum 
GAPDH    glyceraldehyde-3-phosphate dehydrogenase 
GDNF     glial-derived neurotrophic factor 
GFAP     glial fibrillary acidic protein 
GFP     green fluorescent protein 
hFbl     human fibroblasts 
HGF     hepatocyte growth factor 
hMSC     human mesenchymal stromal cells 
hNuclei    human nuclei 
Iba1     ionized calcium binding adaptor molecule 1 
IL     interleukin  
LPS     lipopolysaccharide 
MAP1b    microtubule-associated protein 1b 
MAPT     microtubule-associated protein tau 
MBP     myelin basic protein 
MSC     mesenchymal stromal cell 
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NEUROD6    neurogenic differentiation 6 
NF200    neurofilament 200 kDa 
NFH     neurofilament heavy 
NFL     neurofilament medium 
NFL    neurofilament light 
NGF     nerve growth factor 
NSE     neuron-specific enolase 
NT     neurotrophin 
OEC     olfactory ensheathing cell 
PBS     phosphate-buffered saline 
PDGF (-BB)   platelet-derived growth factor (BB) 
PFA     paraformaldehyde 
PGK     phosphoglycerate kinase 
RAU     random arbitrary units 
SCI     spinal cord injury 
SDF     stromal-derived factor 
SYP     synaptophysin 
TH     tyrosine hydroxylase 
TLR     toll-like receptor 
VEGF     vascular endothelial growth factor 
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